Abstract
Viral infections of the external eye range from benign to malignant, from a transient keratitis of mononucleosis to the progressive sarcoma associated with AIDS. Transient acute follicular conjunctivitis, with or without keratitis, may be seen with any of the DNA or RNA agents. The former include the herpes viruses, adenoviruses, poxviruses, and papillomaviruses. The latter include the paramyxoviruses (measles, mumps, and Newcastle disease), the retrovirus (HIV), the picornavirus of acute hemorrhagic conjunctivitis, the togaviruses (rubella and arbovirus), and the orthomyxovirus (influenza). With the exception of congenital rubella, the RNA viruses tend to be more benign and the DNA viruses more associated with a notable ocular morbidity and loss of vision. Many, but not all, of the organisms that most seriously affect the anterior segment are amenable to therapy; however, some progress with our best efforts, and others need only palliative treatment. Diagnostic tests and currently available antiviral and antiinflammatory agents are briefly reviewed, followed by a discussion of the clinical disease and management of the major anterior ocular viral infections.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
White DFF, editor. Laboratory diagnosis of viral disease. San Diego, CA: Academic Press; 1994. p. 191–218.
Baron E, Peterson L, Finegold S, editors. Laboratory methods in basic virology. St Louis, MO: Mosby-Year Book; 1994. p. 634–88.
Hooks J. In: Tabbara K, Hyndiuk R, editors. Ocular virology. Boston, MA: Little Brown; 1996. p. 99–114.
Kinchington P. In: Smolin G, Thoft R, editors. Virology. Boston, MA: Little Brown; 1994. p. 169–82.
Pavan-Langston D. In: Foster S, Azar D, Dohlman C, editors. Viral disease of the ocular anterior segment: basic science and clinical disease. Philadelphia, PA: Lippincott, Williams & Wilkins; 2005. p. 297–397.
Fields B, Knipe D, Howley P. Virology. 3rd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 1996.
Tei M, Nishida K, Kinoshita S. Polymerase chain reaction detection of herpes simplex virus in tear fluid from atypical herpetic epithelial keratitis after penetrating keratoplasty. Am J Ophthalmol. 1996;122:732–5.
Yamamoto S, Shimomura Y, Kinoshita S, et al. Detection of herpes simplex virus DNA in human tear film by the polymerase chain reaction. Am J Ophthalmol. 1994;117:160–3.
Yamashita T. Diagnostic tests: Varicella-zoster virus. Nippon Rinsho. 2005;63(Suppl 7):294–6.
Alvarado J, Underwood J, Green R, et al. Detection of herpes simplex viral DNA in the iridocorneal endothelial syndrome. Arch Ophthalmol. 1994;112:1610–09.
Yamamoto S, Pavan-Langston D, Tada R, et al. Possible role of herpes simplex virus in the origin of Posner-Schlossman syndrome. Am J Ophthalmol. 1995;119:796–8.
Kaye SB, Baker K, Bonshek R, et al. Human herpesviruses in the cornea. Br J Ophthalmol. 2000;84:563–71.
Kaye SB, Lynas C, Patterson A, et al. Evidence for herpes simplex viral latency in the human cornea. Br J Ophthalmol. 1991;75:195–200.
McIver CJ, Jacques CF, Chow SS, et al. Development of multiplex PCRs for detection of common viral pathogens and agents of congenital infections. J Clin Microbiol. 2005;43:5102–10.
Kowalski R, Thompson P, Kinchington P, et al. Evaluation of the Smartcycler† II system for the real-time detection of viruses and chlamydia from ocular specimens. Arch Ophthalmol. 2006;124:1135–9.
Gillo V, Fedorko D, Witebsky F. The clinician and the microbiology laboratory. In: Mandell G, Bennett J, Dolin R, editors. Principles and practices of infectious diseases. Philadelphia, PA: Elsevier; 2005. p. 203–42.
Gleaves C, Hondinka R, Johnston S, et al. In: Baron E, editor. Cumtech 15A. Washington, DC: American Public Health Association; 1994. p. 38–56.
Liesegang T. In: Albert D, Jakobiec F, editors. Ocular virology. Philadelphia, PA: WB Saunders; 2000. p. 171–98.
Britt W. In: Goldman L, Ausiello D, editors. Human cytomegalovirus. Philadelphia, PA: Saunders; 2004. p. 1993–5.
Shoji J, Sakimoto T, Inada N, et al. A diagnostic method for herpes simplex keratitis by simultaneous measurement of viral DNA and virus-specific secretory IgA in tears: an evaluation. Jpn J Ophthalmol. 2016;60:294–301.
Kowalski R, Gordon Y. Evaluation of immunologic tests for the detection of ocular herpes simplex virus. Ophthalmology. 1989;96:1583.
Lee S, Gregory A, Storch M, et al. Comparative laboratory diagnosis of experimental herpes simplex keratitis. Am J Ophthalmol. 1990;109:8.
Papesch M, Watkins R. Epstein-Barr virus infectious mononucleosis. Clin Otolaryngol Allied Sci. 2001;26:3–8.
Kieff E. In: Goldman L, Ausiello D, editors. Infectious mononucleosis: Epstein-Barr infection. Philadelphia, PA: Saunders; 2004. p. 1995–9.
Matoba A. In: Pepose J, Holland G, Wilhelmus K, editors. Epstein-Barr virus diseases. St Louis, MO: Mosby; 1996. p. 958–69.
Hazeltine W. Silent HIV infections. N Engl J Med. 1989;320:1487.
Liang TS, Erbelding E, Jacob CA, et al. Rapid HIV testing of clients of a mobile STD/HIV clinic. AIDS Patient Care STDS. 2005;19:253–7.
Gordon Y, Aoki K, Kinchington P. In: Pepose J, Holland G, Wilhelmus K, editors. Adenovirus keratoconjunctivitis. St Louis, MO: Mosby; 1996. p. 877–94.
Behbehani A. In: Lennette E, Lennette D, Lennette E, editors. Poxviruses. Washington, DC: American Public Health Association; 1995. p. 511–20.
Claoue C, De Cock R. The spectrum of herpes simplex virus disease of the anterior segment in the 1990s. Acta Ophthalmol Scand. 1996;74:407–10.
Pavan-Langston D. In: Galasso G, Whitley R, Merigan R, editors. Herpes simplex, adenovirus, Epstein Barr virus, pox in major ocular viral infections. New York: Raven Press; 1997. p. 187–229.
Semba R. The ocular complications of smallpox and smallpox immunization. Arch Ophthalmol. 2003;121:715–9.
Coleman V, Thygeson P, Dawson C, et al. Isolation of virus from herpetic keratitis: influence of idoxuridine on isolation rate. Arch Ophthalmol. 1969;81:22.
Mann L, Woods G. Rapid diagnosis of viral pathogens. Clin Lab Med. 1995;15:389–405.
US Pharmacopeia – Valtrex. Greenwood Village, CO: Thomson Micromedex; 2005. p. 1501–8.
US Pharmacopeia – Famvir. Greenwood Village, CO: Thomson Micromedex; 2005. p. 1390–2.
US Pharmacopeia – Acyclovir. Greenwood City, CO: Thomson Micromedex; 2005. p. 24–32.
Handbook of antimicrobial therapy. In: The medical letter on drugs and therapeutics, 17th edn. New Rochelle: Pages; 2005.
Pavan-Langston D. In: Jaeger E, Tasman W, Wilhelmus K, editors. Ocular pharmacology of antiviral drugs. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004. p. 1–24.
Foster CS. In: Lamberts D, Potter D, editors. Nonsteroidal anti-inflammatory and immunosuppressive agents. Boston, MA: Little, Brown; 1987. p. 173.
Kleinert R, Palmer M. In: Tabbara K, Hyndiuk R, editors. Antiinflammatory agents. Boston, MA: Little, Brown; 1996. p. 301–22.
Pavan-Langston D, Dunkel E. Corticosteroids, immunosuppressive agents, and non-steroidal anti-inflammatory drugs. In: Pavan-Langston D, Dunkel E, editors. Handbook of ocular drug therapy. Boston, MA: Little, Brown; 1991. p. 182–94.
Wilhelmus KR, Dawson CR, Barron BA, et al. Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis. Herpetic Eye Disease Study Group. Br J Ophthalmol. 1996;80:696–67.
Gunduz K, Ozdemir O. Topical cyclosporin as an adjunct to topical acyclovir treatment in herpetic stromal keratitis. Ophthalmic Res. 1997;29:405–8.
Field A, Gottsch J. Persisting epithelial herpes simplex keratitis while on cyclosporin-A ointment. ANZJ Ophthalmol. 1995;23:333–4.
Heiligenhaus A, Steuhl KP. Treatment of HSV-1 stromal keratitis with topical cyclosporin A: a pilot study. Graefes Arch Clin Exp Ophthalmol. 1999;237:435–8.
Remeijer L, Osterhaus A, Verjans G. Human herpes simplex virus keratitis: the pathogenesis revisited. Ocul Immunol Inflamm. 2004;12:255–85.
Cohrs RJ, Laguardia JJ, Gilden D. Distribution of latent herpes simplex virus type-1 and varicella zoster virus DNA in human trigeminal ganglia. Virus Genes. 2005;31:223–7.
Labetoulle M, Auquier P, Conrad H, et al. Incidence of herpes simplex virus keratitis in France. Ophthalmology. 2005;112:888–95.
Bradley H, Markowitz LE, Gibson T, et al. Seroprevalence of herpes simplex virus types 1 and 2: United States, 1999–2010. J Infect Dis. 2014;209:325–33.
Nahmias AJ, Alford CA, Korones SB. Infection of the newborn with herpesvirus hominis. Adv Pediatr. 1970;17:185–226.
Nahmias AJ, Roizman B. Infection with herpes-simplex viruses 1 and 2.3. N Engl J Med. 1973;289:781–9.
Pepose JS, Keadle TL, Morrison LA. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy. Am J Ophthalmol. 2006;141:547–57.
Lafferty W, Coombs R, Benedetti J, et al. Recurrences after oral and genital herpes simplex viral infection. N Engl J Med. 1987;316:1444.
Wilhelmus K. In: Jaeger E, Tasman W, editors. The epidemiology of ocular infection. Philadelphia, PA: Lippincott-Raven; 1998.
Butler TK, Spencer NA, Chan CC, et al. Infective keratitis in older patients: a 4 year review, 1998–2002. Br J Ophthalmol. 2005;89:591–6.
Remeijer L, Maertzdorf J, Buitenwerf J, et al. Corneal herpes simplex virus type 1 superinfection in patients with recrudescent herpetic keratitis. Invest Ophthalmol Vis Sci. 2002;43:358–63.
Chong EM, Wilhelmus KR, Matoba AY, et al. Herpes simplex virus keratitis in children. Am J Ophthalmol. 2004;138:474–5.
Kaufman HE, Azcuy AM, Varnell ED, et al. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci. 2005;46:241–7.
Bell D, Holman R, Pavan-Langston D. Epidemiologic aspect of herpes simplex keratitis. Ann Ophthalmol. 1982;14:421.
Shuster J, Kaufman H, Nesburn A. Statistical analysis of the rate of recurrence of herpes virus ocular epithelial disease. Am J Ophthalmol. 1981;91:328.
HEDS. HEDS: predictors of recurrent herpes simplex virus keratitis. Herpetic Eye Disease Study Group. Cornea. 2001;20:123–8.
HEDS. Psychological stress and other potential triggers for recurrences of herpes simplex virus eye infections. Herpetic Eye Disease Study Group. Arch Ophthalmol. 2000;118:1617–25.
Koelle DM, Ghiasi H. Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Curr Eye Res. 2005;30:929–42.
Nesburn AB, Ramos TV, Zhu X, et al. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine. 2005;23:873–83.
Cunningham AL, Taylor R, Taylor J, et al. Prevalence of infection with herpes simplex virus types 1 and 2 in Australia: a nationwide population based survey. Sex Transm Infect. 2006;82:164–8.
Pivetti-Pezzi P, Accorinti M, Colabelli-Gisoldi RA, et al. Herpes simplex virus vaccine in recurrent herpetic ocular infection. Cornea. 1999;18:47–51.
Belshe RB, Leone PA, Bernstein DI, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34–43.
Keadle TL, Laycock KA, Morris JL, et al. Therapeutic vaccination with vhs(−) herpes simplex virus reduces the severity of recurrent herpetic stromal keratitis in mice. J Gen Virol. 2002;83:2361–5.
Rowe AM, St Leger AJ, Jeon S, et al. Herpes keratitis. Prog Retin Eye Res. 2013;32:88–101.
Looker KJ, Magaret AS, May MT, et al. First estimates of the global and regional incidence of neonatal herpes infection. Lancet Glob Health. 2017;5:e300–9.
Gantt S, Muller WJ. The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention. Clin Dev Immunol. 2013;2013:369172.
Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med. 2009;361:1376–85.
Kimberlin DW. Herpes simplex virus infections of the newborn. Semin Perinatol. 2007;31:19–25.
Patel CD, Backes IM, Taylor SA, et al. Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity. Sci Transl Med. 2019;11(487).
Hutchison D, Smith R, Haughton D. Congenital herpetic keratitis. Arch Ophthalmol. 1975;93:70.
Nahmias AJ, Visintine AM, Caldwell DR, et al. Eye infections with herpes simplex viruses in neonates. Surv Ophthalmol. 1976;21:100–5.
Krolczyk S, Pacheco E, Valencia P, et al. Opsoclonus: an early sign of neonatal herpes encephalitis. J Child Neurol. 2003;18:356–8.
Kimberlin DW, Lin CY, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108:223–9.
Pavan-Langston D. Living with Herpes. New York: Doubleday; 1983.
Azazi M, Gunilla M, Forsgren M. Late ophthalmologic manifestations of neonatal herpes simplex virus infection. Am J Ophthalmol. 1990;109:1–7.
Donoval BA, Passaro DJ, Klausner JD. The public health imperative for a neonatal herpes simplex virus infection surveillance system. Sex Transm Dis. 2006;33:170–4.
Schwartz G, Holland G. Oral acyclovir for the management of herpes simplex keratitis in children. Ophthalmology. 2000;107:278–82.
Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001;108:230–8.
Chang T, Brewer L, Hooper P. Primary herpes simplex iridocyclitis with iris atrophy. Arch Ophthalmol. 1993;111:25–6.
Paven-Langsto D. In: Galasso G, Whitley R, editors. Major ocular viral infections: Herpes simplex, adenovirus, Epstein Barr virus, pox. New York: Raven Press; 1997. p. 187–228.
Yao Y, Inoue Y, Shimomura Y, et al. Primary herpes simplex virus infection with geographic conjunctival ulceration. Am J Ophthalmol. 1994;118:670–1.
Baringer J, Swoveland P. Recovery of Herpes simplex virus from human trigeminal ganglions. N Engl J Med. 1973;288:648.
Bastian F, Rabson A, Yee C, et al. Herpesvirus hominis: isolation from human trigeminal ganglion. Science. 1972;178:306.
Remeijer L, Maertzdorf J, Doornenbal P, et al. Herpes simplex virus 1 transmission through corneal transplantation. Lancet. 2001;357:442.
Sabbaga E, Pavan-Langston D, Bean K, et al. Detection of HSV nucleic acid sequences in the cornea during acute and latent ocular disease. Exp Eye Res. 1988;47:545.
Pavan-Langston D. Herpes simplex virus ocular infections: current concepts of acute, latent and reactivated disease. Trans Am Ophthalmol Soc. 1990;88:727–96.
Ohashi Y, Yamamoto S, Nishida K, et al. Demonstration of herpes simplex virus DNA in idiopathic corneal endotheliopathy. Am J Ophthalmol. 1991;112:419–23.
Asbell P. In: Hyndiuk R, Tabbara K, editors. Viral conjunctivitis. Boston, MA: Little, Brown; 1996. p. 453–70.
Hyndiuk R, Glasser D. In: Tabbara K, Hyndiuk R, editors. Herpes simplex keratitis. Boston, MA: Little, Brown; 1996. p. 361–86.
Barnes S, Pavan-Langston D, Azar D. In: Mandell G, Bennett J, Dolin R, editors. Microbial keratitis, in principles and practice of infectious diseases. Philadelphia, PA: Elsevier; 2005. p. 1395–406.
Pavan-Langston D. In: Albert D, Jakobiec F, editors. Viral disease of the cornea and external eye. Philadelphia, PA: WB Saunders; 2000. p. 846–93.
Whitley RJ. Herpes simplex virus in children. Curr Treat Options Neurol. 2002;4:231–7.
Burnette T, deMiranda P. Purification and characterization of an enzyme from rat live that hydrolyzes 256487, the L-valyl ester prodrug of acyclovir (Zovirax). Antiviral Res. 1993;20(Suppl 1):115.
Weller S, Blum M, Smiley M. Phase I pharmacokinetics of the acyclovir prodrug, valacyclovir. Antiviral Res. 1993;20(Suppl 1):144.
Perry CM, Wagstaff AJ. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections. Drugs. 1995;50:396–415.
Labetoulle M, Kucera P, Ugolini G, et al. Neuronal propagation of HSV1 from the oral mucosa to the eye. Invest Ophthalmol Vis Sci. 2000;41:2600–6.
Claoue C, Hill T, Blyth W, et al. Clinical findings after zosteriform spread of herpes simplex virus to the eye of the mouse. Curr Eye Res. 1987;6:281.
Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357:1513–8.
Pavan-Langston D. In: Galasso G, Whitley R, Merrigan T, editors. Major ocular viral infections. New York: Raven Press; 1990. p. 183.
Cockerham GC, Bijwaard K, Sheng ZM, et al. Primary graft failure: a clinicopathologic and molecular analysis. Ophthalmology. 2000;107:2083–90; discussion 2090–2091.
Borderie VM, Meritet JF, Chaumeil C, et al. Culture-proven herpetic keratitis after penetrating keratoplasty in patients with no previous history of herpes disease. Cornea. 2004;23:118–24.
Cleator G, Klapper P, Dennett C, et al. Corneal donor infection by herpes simplex virus: herpes simplex virus DNA in donor corneas. Cornea. 1994;13:294–304.
Rong BL, Pavan-Langston D, Weng QP, et al. Detection of herpes simplex virus thymidine kinase and latency-associated transcript gene sequences in human herpetic corneas by polymerase chain reaction amplification. Invest Ophthalmol Vis Sci. 1991;32:1808–15.
Openshaw H, Asher L, Wohlenberg C, et al. Acute and latent infection of sensory ganglia with herpes simplex virus: immune control and virus reactivation. J Gen Virol. 1979;44:205.
Baringer J. The virology of Herpes simplex virus infection in humans. Surv Ophthalmol. 1976;21:171.
Blyth W, Hill T, Field H, et al. Reactivation of Herpes simplex virus infection by ultraviolet light and possible involvement of prostaglandins. J Gen Virol. 1976;33:547.
Klein R. Pathogenic mechanisms of recurrent herpes simplex virus infections. Arch Virol. 1976;51:1.
Klein R. The pathogenesis of acute, latent, and recurrent herpes simplex infections. Arch Virol. 1982;72:143–68.
Kwon B, Gangarosa L, Burch K, et al. Induction of ocular herpes simplex virus shedding by iontophoresis of epinephrine into rabbit cornea. Invest Ophthalmol. 1981;21:442.
Laibson P, Kilbrick S. Reactivation of herpetic keratitis by epinephrine in rabbit. Arch Ophthalmol. 1966;75:254.
Nesburn A, Dickenson M, Radnoti M, et al. Experimental reactivation of ocular herpes simplex in rabbits. Surv Ophthalmol. 1976;21:185.
Openshaw H, Puga A, Notkins A. Herpes simplex virus infection in sensory ganglia: immune control, latency, and reactivation. Fed Proc. 1979;38:2660–4.
Kaufman HE, Varnell ED, Toshida H, et al. Effects of topical unoprostone and latanoprost on acute and recurrent herpetic keratitis in the rabbit. Am J Ophthalmol. 2001;131:643–6.
Morales J, Shihab ZM, Brown SM, et al. Herpes simplex virus dermatitis in patients using latanoprost. Am J Ophthalmol. 2001;132:114–6.
Schumer RA, Camras CB, Mandahl AK. Putative side effects of prostaglandin analogs. Surv Ophthalmol. 2002;47(Suppl 1):S219.
Bean G, Reardon G, Zimmerman TJ. Association between ocular herpes simplex virus and topical ocular hypotensive therapy. J Glaucoma. 2004;13:361–4.
Gordon YJ, Yates KA, Mah FS, et al. The effects of Xalatan on the recovery of ocular herpes simplex virus type 1 (HSV-1) in the induced reactivation and spontaneous shedding rabbit models. J Ocul Pharmacol Ther. 2003;19:233–45.
Asbell P. Valaciclovir for prevention of recurrent herpes simplex virus eye disease after Excimer laser photokeratectomy. Trans Am Ophthalmol Soc. 2000;98:285–303.
Dhaliwal DK, Romanowski EG, Yates KA, et al. Valacyclovir inhibition of recovery of ocular herpes simplex virus type 1 after experimental reactivation by laser in situ keratomileusis. J Cataract Refract Surg. 2001;27:1288–93.
de Rojas Silva MV, Diez-Feijoo E, Javaloy J, et al. Prophylactic perioperative antiviral therapy for LASIK in patients with inactive herpetic keratitis. J Refract Surg. 2006;22:404–6.
Reed SY, Shin DH, Birt CM, et al. Herpes simplex keratitis following argon laser trabeculoplasty. Ophthalmic Surg. 1994;25:640.
Vrabec M, Durrie D, Chase D. Recurrence of herpes simplex after excimer laser keratectomy. Am J Ophthalmol. 1992;114:96–7.
Deai T, Fukuda M, Tomoda Y, et al. Excimer laser photokeratectomy reactivates latent herpes simplex virus. Jpn J Ophthalmol. 2004;48:570–2.
Egerer U-D, Stary A. Erosive-ulcerative herpes simplex blepharitis. Arch Ophthalmol. 1980;98:1760.
Jakobiec F, Srinivasan D, Gamboa E. Recurrent herpetic angular blepharitis in an adult. Am J Ophthalmol. 1979;88:744.
Foster WJ Jr, Kraus MD, Custer PL. Herpes simplex virus dacryoadenitis in an immunocompromised patient. Arch Ophthalmol. 2003;121:911–3.
HEDS. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group. N Engl J Med. 1998;339:300–6.
McLean CJ, Rose GE. Postherpetic lacrimal obstruction. Ophthalmology. 2000;107:496–9.
Ameye C, Maudgal P, Missotten L. In: Maudgal P, Missotten L, editors. Primary ocular HSV infections in adults. Dordrecht: W Junk; 1985. p. 133.
Brown DC, Nesburn AB, Nauheim JS, et al. Recurrent herpes simplex conjunctivitis. Arch Ophthalmol. 1968;79:733–5.
Rosenfeld SI, Alfonso EC, Gollamudi S. Recurrent herpes simplex infection in a conjunctival flap. Am J Ophthalmol. 1993;116:242–4.
Patterson A. Management of ocular herpes simplex. Br J Ophthalmol. 1967;51:494–5.
Pavan-Langston D, editor. Diagnosis and management of herpes simplex ocular infection. Boston, MA: Little, Brown; 1975. p. 19–35.
Liesegang T. Ocular herpes simplex infection: pathogenesis and current therapy. Mayo Clin Proc. 1988;63:1092.
Holland EJ, Schwartz GS. Classification of herpes simplex virus keratitis. Cornea. 1999;18:144–54.
Wilhelmus KR, Falcon MG, Jones BR. Bilateral herpetic keratitis. Br J Ophthalmol. 1981;65:385–7.
Souza PM, Holland EJ, Huang AJ. Bilateral herpetic keratoconjunctivitis. Ophthalmology. 2003;110:493–6.
Pavan-Langston D. In: Smolin G, Thoft R, editors. Herpetic infections. Boston, MA: Little, Brown; 1994. p. 183–214.
Ahonen R, Vannas A. In: Maudgal P, Missotten L, editors. Clinical comparison between herpes simplex and herpes zoster ocular infections. Dordrecht: Fr. W. Junk; 1985. p. 389.
Jones B, Falcon M, Williams H, et al. Symposium on herpes simplex eye disease: objectives in therapy. Trans Ophthalmol Soc UK. 1977;97:305.
Kodama T, Hayasaka S, Setogawa T. Immunofluorescent staining and corneal sensitivity in patients suspected of having herpes simplex keratitis. Am J Ophthalmol. 1992;113:187–9.
Van Horn DL, Edelhauser HE, Schultz RO. Experimental herpes simplex keratitis. Early alterations of corneal epithelium and stroma. Arch Ophthalmol. 1970;84:67–75.
Baum J. Morphogenesis of the dendritic figure in herpes simplex keratitis: a negative study. Am J Ophthalmol. 1970;70:722.
Collum LM, McGettrick P, Akhtar J, et al. Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration. Br J Ophthalmol. 1986;70:435–8.
Hung S, Patterson A, Clark D, et al. Oral acyclovir in management of dendritic herpetic corneal ulceration. Br J Ophthalmol. 1984;68:398.
Schwab IR. Oral acyclovir in the management of herpes simplex ocular infections. Ophthalmology. 1988;95:423–30.
Simon AL, Pavan-Langston D. Long-term oral acyclovir therapy. Effect on recurrent infectious herpes simplex keratitis in patients with and without grafts. Ophthalmology. 1996;103:1399–405.
HEDS. Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis. Herpetic Eye Disease Study Group. Arch Ophthalmol. 2000;118:1030–6.
Margolis TP, Ostler HB. Treatment of ocular disease in eczema herpeticum. Am J Ophthalmol. 1990;110:274–9.
Wilhelmus KR. The treatment of herpes simplex virus epithelial keratitis. Trans Am Ophthalmol Soc. 2000;98:505–32.
Iglesia DD, Stepp MA. Disruption of the basement membrane after corneal debridement. Invest Ophthalmol Vis Sci. 2000;41:1045–53.
Labetoulle M. The latest in herpes simplex keratitis therapy. J Fr Ophtalmol. 2004;27:547–57.
Goins K. New insights into the diagnosis and treatment of neurotrophic keratopathy. Ocul Surf. 2005;3:96–110.
Wilson S, Netto M, Ambrosio R Jr. Corneal cells: chatty in development, homeostasis, wound healing, and disease. Am J Ophthalmol. 2003;136:530–6.
Muller LJ, Marfurt CF, Kruse F, et al. Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76:521–42.
Lindsay RM, Harmar AJ. Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature. 1989;337:362–4.
Suuronen EJ, Nakamura M, Watsky MA, et al. Innervated human corneal equivalents as in vitro models for nerve-target cell interactions. FASEB J. 2004;18:170–2.
Wilson SE, Liu JJ, Mohan RR. Stromal-epithelial interactions in the cornea. Prog Retin Eye Res. 1999;18:293–309.
Beuerman RW, Schimmelpfennig B. Sensory denervation of the rabbit cornea affects epithelial properties. Exp Neurol. 1980;69:196–201.
Lim CH. Innervation of the cornea of monkeys and the effects of denervation. Br J Physiol Opt. 1976;31:38–42.
Netto MV, Mohan RR, Ambrosio R Jr, et al. Wound healing in the cornea: a review of refractive surgery complications and new prospects for therapy. Cornea. 2005;24:509–22.
Rosenberg ME, Tervo TM, Muller LJ, et al. In vivo confocal microscopy after herpes keratitis. Cornea. 2002;21:265–9.
Cavanagh C, Colley A, Pihlaja D. Persistent corneal epithelial defects. Int Ophthalmol Clin. 1979;19:197.
Eakins KE, Whitelocke RA, Bennett A, et al. Prostaglandin-like activity in ocular inflammation. Br Med J. 1972;3:452–3.
Khodadoust AA, Silverstein AM, Kenyon DR, et al. Adhesion of regenerating corneal epithelium. The role of basement membrane. Am J Ophthalmol. 1968;65:339–48.
Cavanagh H. Herpetic ocular disease: therapy of persistent epithelial defects. Int Ophthalmol Clin. 1975;15:67.
Kaufman H. Epithelial erosion syndrome: metaherpetic keratitis. Am J Ophthalmol. 1964;57:983.
VanBijsterveld O, deKoning E. In: Blodi F, editor. Trophic herpetic corneal ulcers. New York: Churchill Livingstone; 1984. p. 29.
Fukuda M, Deai T, Hibino T, et al. Quantitative analysis of herpes simplex virus genome in tears from patients with herpetic keratitis. Cornea. 2003;22:S55–60.
Kaufman H, Uotila M, Gasset A, et al. The medical uses of soft contact lenses. Trans Am Acad Ophthalmol Otolaryngol. 1971;75:361.
Karlgard CC, Jones LW, Moresoli C. Survey of bandage lens use in North America, October–December 2002. Eye Contact Lens. 2004;30:25–30.
Lass J, Berman M, Campbell R, et al. Treatment of experimental herpetic interstitial keratitis with medroxyprogesterone. Arch Ophthalmol. 1980;98:520–5.
Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res. 1995;28:281–90.
Beutner KR, Friedman DJ, Forszpaniak C, et al. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 1995;39:1546–53.
Mindel A. Long-term clinical and psychological management of genital herpes. J Med Virol. 1993;1:39–44.
Strauss S, Croen K, Sawyer M, et al. Acyclovir suppression of frequently recurring genital herpes: efficacy and diminishing need during successive years of treatment. JAMA. 1988;260:2227–30.
Ralph RA. Tetracyclines and the treatment of corneal stromal ulceration: a review. Cornea. 2000;19:274–7.
Vote BJ, Elder MJ. Cyanoacrylate glue for corneal perforations: a description of a surgical technique and a review of the literature. Clin Exp Ophthalmol. 2000;28:437–42.
Pavan-Langston D. In: Swartz M, Remington J, editors. Herpes keratitis – clinical features, diagnosis, treatment and prophylaxis. Boston, MA: Blackwell Science; 2000. p. 298–324.
Refojo M, Dohlman C, Koliopoulos J. Adhesives in ophthalmology: a review. Surv Ophthalmol. 1971;15:217.
Berman MB, Barber JC, Talamo RC, et al. Corneal ulceration and the serum antiproteases. I. Alpha 1-antitrypsin. Invest Ophthalmol. 1973;12:759–70.
Lambiase A, Manni L, Rama P, et al. Clinical application of nerve growth factor on human corneal ulcer. Arch Ital Biol. 2003;141:141–8.
Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;338:1174–80.
Dekaris I, Gabric N, Mravicic I, et al. Multilayer vs. monolayer amniotic membrane transplantation for deep corneal ulcer treatment. Coll Antropol. 2001;25(Suppl):23–8.
Dogru M, Tsubota K. Current concepts in ocular surface reconstruction. Semin Ophthalmol. 2005;20:75–93.
Kruse FE, Rohrschneider K, Volcker HE. Techniques for reconstruction of the corneal surface by transplantation of preserved human amniotic membrane. Ophthalmology. 1999;96:673–8.
Kruse FE, Rohrschneider K, Volcker HE. Multilayer amniotic membrane transplantation for reconstruction of deep corneal ulcers. Ophthalmology. 1999;106:1504–10; discussion 1511.
Kenyon KR. Amniotic membrane: mother’s own remedy for ocular surface disease. Cornea. 2005;24:639–42.
Solomon A, Meller D, Prabhasawat P, et al. Amniotic membrane grafts for nontraumatic corneal perforations, descemetoceles, and deep ulcers. Ophthalmology. 2002;109:694–703.
Naito J, Mott KR, Osorio N, et al. Herpes simplex virus type 1 immediate-early protein ICP0 diffuses out of infected rabbit corneas. J Gen Virol. 2005;86:2979–88.
Holbach LM, Asano N, Naumann GO. Infection of the corneal endothelium in herpes simplex keratitis. Am J Ophthalmol. 1998;126:592–4.
Kaufman H, Rayfield M. In: Kaufman H, Mcdonald M, Barron B, et al., editors. Viral conjunctivitis and keratitis. New York: Churchill Livingstone; 1988. p. 299–332.
Pavan-Langston D. Herpes simplex of the ocular anterior segment. Curr Clin Top Infect Dis. 2000;20:298–324.
Pepose J. Herpes simplex keratitis: role of viral infection versus immune response. Surv Ophthalmol. 1991;35:345–52.
Tabbara KF. Treatment of herpetic keratitis. Ophthalmology. 2005;112:1640.
Abghari S, Stulting R. Recovery of Herpes simplex virus from ocular tissues of latently infected mice. Invest Ophthalmol Vis Sci. 1988;29:239.
Brik D, Dunkel E, Pavan-Langston D. Herpetic keratitis: persistence of viral particles despite topical and systemic antiviral therapy. Report of two cases and review of the literature. Arch Ophthalmol. 1993;111:522–7.
Dawson C, Togni B, Moore T Jr. Structural changes in chronic herpetic keratitis: studied by light and electron microscopy. Arch Ophthalmol. 1968;79:740.
Rong BL, Dunkel EC, Pavan-Langston D. Molecular analysis of acyclovir-induced suppression of HSV-1 replication in rabbit corneal cells. Invest Ophthalmol Vis Sci. 1988;29:928–32.
Tullo A, Easty D, Shimeld C, et al. Isolation of Herpes simplex virus from corneal discs of patients with chronic stromal keratitis. Trans Ophthalmol Soc UK. 1985;104:159.
Brandt CR. The role of viral and host genes in corneal infection with herpes simplex virus type 1. Exp Eye Res. 2005;80:607–21.
Kaufman H, Centifanto-Fitzgerald Y, Varnell E. Herpes simplex keratitis. Ophthalmology. 1983;90:700.
Spear P. In: Roizman B, editor. Glycoproteins specified by Herpes simplex viruses. New York: Plenum Press; 1985. p. 315.
Kaufman H, Varnell E, Centifanto Y, et al. Effect of the herpes simplex virus genome on the response of infection to corticosteroids. Am J Ophthalmol. 1985;100:114.
Keadle TL, Usui N, Laycock KA, et al. IL-1 and TNF-alpha are important factors in the pathogenesis of murine recurrent herpetic stromal keratitis. Invest Ophthalmol Vis Sci. 2000;41:96–102.
Tumpey TM, Cheng H, Yan XT, et al. Chemokine synthesis in the HSV-1-infected cornea and its suppression by interleukin-10. J Leukoc Biol. 1998;63:486–92.
Yan XT, Tumpey TM, Kunkel SL, et al. Role of MIP-2 in neutrophil migration and tissue injury in the herpes simplex virus-1-infected cornea. Invest Ophthalmol Vis Sci. 1998;39:1854–62.
O’Brien WJ, Guy J, Taylor JL. Pathogenesis of corneal oedema associated with herpetic eye disease. Br J Ophthalmol. 1990;74:723–30.
Vollstedt S, Arnold S, Schwerdel C, et al. Interplay between alpha/beta and gamma interferons with B, T, and natural killer cells in the defense against herpes simplex virus type 1. J Virol. 2004;78:3846–50.
Streilein JW, Dana MR, Ksander BR. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol Today. 1997;18:443–9.
Tumpey TM, Fenton R, Molesworth-Kenyon S, et al. Role for macrophage inflammatory protein 2 (MIP-2), MIP-1alpha, and interleukin-1alpha in the delayed-type hypersensitivity response to viral antigen. J Virol. 2002;76:8050–7.
Ellison AR, Yang L, Cevallos AV, et al. Analysis of the herpes simplex virus type 1 UL6 gene in patients with stromal keratitis. Virology. 2003;310:24–8.
Verjans GM, Remeijer L, Mooy CM, et al. Herpes simplex virus-specific T cells infiltrate the cornea of patients with herpetic stromal keratitis: no evidence for autoreactive T cells. Invest Ophthalmol Vis Sci. 2000;41:2607–12.
Biswas PS, Rouse BT. Early events in HSV keratitis – setting the stage for a blinding disease. Microbes Infect. 2005;7:799–810.
Banerjee K, Biswas PS, Kumaraguru U, et al. Protective and pathological roles of virus-specific and bystander CD8+ T cells in herpetic stromal keratitis. J Immunol. 2004;173:7575–83.
Osorio Y, Cai S, Hofman FM, et al. Involvement of CD8+ T-cells in exacerbation of corneal scarring in mice. Curr Eye Res. 2004;29:145–51.
Banerjee K, Biswas PS, Rouse BT. Elucidating the protective and pathologic T cell species in the virus-induced corneal immunoinflammatory condition herpetic stromal keratitis. J Leukoc Biol. 2005;77:24–32.
Meyers-Elliott RH, Chitjian PA. Induction of cell-mediated immunity in herpes simplex virus keratitis. Kinetics of lymphocyte transformation and the effect of antiviral antibody. Invest Ophthalmol Vis Sci. 1980;19:920–9.
Meyers-Elliott RH, Pettit TH, Maxwell WA. Viral antigens in the immune ring of herpes simplex stromal keratitis. Arch Ophthalmol. 1980;98:897–904.
Schwartz GS, Harrison AR, Holland EJ. Etiology of immune stromal (interstitial) keratitis. Cornea. 1998;17:278–81.
Holbach LM, Font RL, Naumann GO. Herpes simplex stromal and endothelial keratitis. Granulomatous cell reactions at the level of Descemet’s membrane, the stroma, and Bowman’s layer. Ophthalmology. 1990;97:722–8.
Meyers RL, Pettit TH. The pathogenesis of corneal inflammation due to herpes simplex virus. I. Corneal hypersensitivity in the rabbit. J Immunol. 1973;111:1031–42.
Robin JB, Steigner JB, Kaufman HE. Progressive herpetic corneal endotheliitis. Am J Ophthalmol. 1985;100:336–7.
Sundmacher R. In: Sundmacher R, Munich JF, editors. A clinico-virologic classification of herpetic anterior segment disease with special reference to intraocular herpes: Bergmann Verlag; 1981. p. 203.
Sundmacher R, Neumann-Haefelin D. Herpes simplex virus isolations from the aqueous humor of patients suffering from focal iritis, endotheliitis, and prolonged disciform keratitis with glaucoma (author’s transl). Klin Monbl Augenheilkd. 1979;175:488–501.
Sutcliffe E, Baum J. Acute idiopathic corneal endotheliitis. Ophthalmology. 1984;91:1161.
Amano S, Oshika T, Kaji Y, et al. Herpes simplex virus in the trabeculum of an eye with corneal endotheliitis. Am J Ophthalmol. 1999;127:721–2.
Olsen TW, Hardten DR, Meiusi RS, et al. Linear endotheliitis. Am J Ophthalmol. 1994;117:468–74.
Cheng CK, Chang SW, Hu FR. Acyclovir treatment for linear endotheliitis on grafted corneas. Cornea. 1995;14:311–5.
Easty D, Shimeld C, Claoue C, et al. Herpes simplex virus isolation in chronic stromal keratitis: human and laboratory studies. Curr Eye Res. 1987;6:69.
Hogan M. Corneal transplantation in the treatment of herpetic disease of the cornea. Am J Ophthalmol. 1957;43:147.
Pavan-Langston D, Nesburn AB. The chronology of primary herpes simplex infection of the eye and adnexal glands. Arch Ophthalmol. 1968;80:258–64.
Collin H, Abelson M. Herpes simplex virus in human cornea, retrocorneal fibrous membrane and vitreous. Arch Ophthalmol. 1976;94:1726.
Gupta K, Hoepner J, Streeten B. Pseudomelanoma of the iris in herpes simplex keratoiritis. Ophthalmology. 1986;93:1524.
HEDS. A controlled trial of oral acyclovir for iridocyclitis caused by herpes simplex virus. The Herpetic Eye Disease Study Group. Arch Ophthalmol. 1996;114:1065–72.
Pavan-Langston D, Brockhurst RJ. Herpes simplex panuveitis. A clinical report. Arch Ophthalmol. 1969;81:783–7.
Gaynor BD, Margolis TP, Cunningham ET Jr. Advances in diagnosis and management of herpetic uveitis. Int Ophthalmol Clin. 2000;40:85–109.
Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol. 2000;106:1019–32.
Global. HIV infections doubled since 1995. AIDS Policy Law. 2005;21:1–4.
Del Rio C, Curran J. In: Mandell G, Bennett J, Dolin R, editors. Epidemiology and prevention of acquired immunodeficiency syndrome and human immunodeficiency virus infection. Philadelphia, PA: Elsevier; 2005. p. 1477–506.
Merson M, Piot P. In: Mandell G, Bennett J, Dolin R, editors. Global perspectives on human immunodeficiency virus infection and acquired immunodeficiency syndrome. Philadelphia, PA: Elsevier; 2005. p. 1465–77.
Fleming PL, Byers R, Sweeney P, et al. HIV prevalence in the United States. In: Fleming PL, Byers R, Sweeney P, et al., editors. 9th Conference on Retroviruses, Seattle, WA, February 24–28; 2002.
Kaplan MH, Sadick N, McNutt NS, et al. Dermatologic findings and manifestations of acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol. 1987;16:485–506.
Leyden J, Baker B. Localized herpes simplex infections in atopic dermatitis. Arch Dermatol. 1979;115:311–4.
Ryan-Graham MA, Durand M, Pavan-Langston D. AIDS and the anterior segment. Int Ophthalmol Clin. 1998;38:241–63.
Vestey J, Howie S, Norval M, et al. Immune responses to herpes simplex virus in patients with facial herpes simplex and those with eczema herpeticum. Br J Dermatol. 1988;118:775–9.
Garrity J, Liesegang T. Ocular complications of atopic dermatitis. Can J Ophthalmol. 1984;19:21.
Binder P. Review of treatment of ocular Herpes simplex infections in the neonate and immunocompromised host. Cornea. 1985;3:178.
Mines J, Kaplan H. Acquired immune deficiency syndrome (AIDS): the disease and its ocular manifestations. Int Ophthalmol Clin. 1986;26:73–85.
Ryan M, Pavan-Langston D, Durand M. In: Io CL, editor. AIDS and the anterior segment. Philadelphia, PA: Lippincott-Raven; 1997. p. 241–64.
Cunningham ET Jr, Margolis TP. Ocular manifestations of HIV infection. N Engl J Med. 1998;339:236–44.
Young T, Robin J, Holland G, et al. Herpes simplex keratitis in patients with acquired immune deficiency syndrome. Ophthalmology. 1989;96:1476–81.
Rosenwasser G, Greene W. Simultaneous herpes simplex types 1 and 2 keratitis in acquired immune deficiency syndrome. Am J Ophthalmol. 1992;113:102–3.
Hodge W, Margolis T. Herpes simplex virus keratitis among patients who are positive or negative for human immunodeficiency virus. Ophthalmology. 1997;104:120–4.
Hodge W, Seiff S, Margolis T. Ocular opportunistic infection incidences among patients who are HIV positive compared to patients who are HIV negative. Ophthalmology. 1998;105:895–900.
Ng WT, Versace P. Ocular association of HIV infection in the era of highly active antiretroviral therapy and the global perspective. Clin Exp Ophthalmol. 2005;33:317–29.
Balfour H. Resistance of herpes simplex to acyclovir. Ann Intern Med. 1983;98:404.
Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus. Dermatol Clin. 2003;21:311–20.
Ramos-Gomez F, Greenspan D, Oleske J. In: Oleske J, Denny T, editors. Pediatric HIV: orofacial manifestations. New York: New Jersey Medical School; 1994. p. 1–5.
Minkovitz J, Pepose J. Topical interferon alpha-2A treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient. Cornea. 1995;14:326–30.
Corey L, Holmes K. Therapy for human immunodeficiency virus infection – what have we learned? N Engl J Med. 1996;335:1142–4.
Hammer S, Katzenstein D, Hughes M, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med. 1996;335:1081–90.
Nimura M, Nishikawa T. Treatment of eczema herpeticum with oral acyclovir. Am J Med. 1988;85:49–54.
Colin J, Baikoff G, Sourdille P. Lamellar graft in the treatment of herpes simplex ocular (author’s transl). J Fr Ophtalmol. 1978;1:501–5.
Ludwig K, Bechmann M, Welge-Lussen U, et al. New automated microkeratome for trepanation of lamellar keratoplasty. Ophthalmology. 2002;99:384–9.
Weiss N, Jones B. Problems of corneal grafting in herpetic keratitis. Ciba Found Symp. 1973;15:220.
Alino AM, Perry HD, Kanellopoulos AJ, et al. Conjunctival flaps. Ophthalmology. 1998;105:1120–3.
Gundersen T. Conjunctival flaps in treatment of corneal disease. Arch Ophthalmol. 1958;6:880.
Thoft RA. Conjunctival transplantation. Arch Ophthalmol. 1977;95:1425.
Branco BC, Gaudio PA, Margolis TP. Epidemiology and molecular analysis of herpes simplex keratitis requiring primary penetrating keratoplasty. Br J Ophthalmol. 2004;88:1285–8.
Al-Yousuf N, Mavrikakis I, Mavrikakis E, et al. Penetrating keratoplasty: indications over a 10 year period. Br J Ophthalmol. 2004;88:998–1001.
Epstein R, Seedor J, Dreizen N, et al. Penetrating keratoplasty for herpes simplex keratitis and keratoconus: allograft rejection and survival. Ophthalmology. 1987;94:935–44.
Rapuano C, Cohen E, Brady S, et al. Indications for and outcomes of repeat penetrating keratoplasty. Am J Ophthalmol. 1990;109:689–95.
Mathers WD, Jester JV, Lemp MA. Return of human corneal sensitivity after penetrating keratoplasty. Arch Ophthalmol. 1988;106:210–1.
Langston RH, Pavan-Langston D. Penetrating keratoplasty for herpetic keratitis: decision-making and management. Int Ophthalmol Clin. 1975;15:125–40.
Boisjoly H, Roy R, Dube I, et al. HLA-A, B and DR matching in corneal transplantation. Ophthalmology. 1986;93:1290.
Koay PY, Lee WH, Figueiredo FC. Opinions on risk factors and management of corneal graft rejection in the United Kingdom. Cornea. 2005;24:292–6.
Croen K, Ostrove J, Dragovic L, et al. Latent Herpes simplex virus in human trigeminal ganglia: detection of an immediate early gene “anti-sense” transcript by in situ hybridization. N Engl J Med. 1987;317:1427.
Stevens J, Wagner E, Devi-Rao G, et al. RNA complimentary to a herpes virus alpha gene mRNA is prominent in latently infected neurons. Science. 1987;235:1056.
Croen K, Ostrove J, Dragovic L, et al. Patterns of gene expression and sites of latency in human ganglia are different for varicella-zoster and herpes simplex viruses. Proc Natl Acad Sci U S A. 1988;85:9773–7.
Mannis M, Plotnik R, Schwab I, et al. Herpes simplex dendritic keratitis after keratoplasty. Am J Ophthalmol. 1991;111:480–4.
Liekfeld A, Jaeckel C, Pleyer U, et al. Analysis of the aqueous humor in keratoplasty patients with keratitis. Initial results. Ophthalmology. 2001;98:456–9.
Dolin R, Reichman R, Mazur M, et al. Herpes zoster varicella infections in immunosuppressed patients. Ann Intern Med. 1978;89:375.
Ragozzino M, Melton M, Kurland L, et al. Population-based study of herpes zoster and its sequelae. Medicine. 1982;61:310.
Hicks CR, Crawford GJ, Tan DT, et al. Outcomes of implantation of an artificial cornea, AlphaCor: effects of prior ocular herpes simplex infection. Cornea. 2002;21:685–90.
Kahn B, Pavan-Langston D. In: Gragoudas E, Vattas D, Hatten M, editors. Clinical manifestations and treatment modalities in Herpes simplex virus of the ocular anterior segment, vol. 44. Philadelphia, PA: Lippincott, Williams & Wilkins; 2004. p. 103–34.
Ma JJ, Graney JM, Dohlman CH. Repeat penetrating keratoplasty versus the Boston keratoprosthesis in graft failure. Int Ophthalmol Clin. 2005;45:49–59.
Kahn B, Aqualvella J, Harissi-Dagher M, et al. The Boston keratoprosthesis in herpetic keratitis. Arch Ophthalmol. 2007;125:745–9.
Basak SK, Basak S. Descemet membrane endothelial keratoplasty in irreversible corneal edema due to herpes simplex virus endotheliitis. Cornea. 2020;39:8–12.
Pavan-Langston D, Yamamoto S, Dunkel E. Delayed herpes zoster pseudodendrites. Arch Ophthalmol. 1995;113:1381–5.
Preblud S, D’Angela I. Age specific risks of varicella complication. Pediatrics. 1981;68:14.
Preblud S, D’Angelo I. Chicken pox in the United States, 1972–1977. J Infect Dis. 1979;140:257–63.
Edwards T. Ophthalmic complications of varicella. J Pediatr Ophthalmol. 1965;2:37.
Lambert SR, Taylor D, Kriss A, et al. Ocular manifestations of the congenital varicella syndrome. Arch Ophthalmol. 1989;107:52.
Gershon A. In: Krugman S, Gershon A, editors. Varicella in mother and infant. New York: Alan R. Liss Inc; 1975.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84.
Gershon A, Steinberg S. Antibody responses to varicella-zoster virus and the role of antibody in host defense. Am J Med Sci. 1981;282:12–7.
Wilson FI. In: Tabbara K, Hyndiuk R, editors. Varicella and Herpes zoster ophthalmicus. Boston, MA: Little, Brown; 1996. p. 387–400.
Pavan-Langston D, Dunkel E. In: Pepose J, Holland G, Wilhelmus K, editors. Varicella-zoster of the anterior segment. Philadelphia, PA: Mosby; 1996. p. 946–85.
Nesburn A, Borit A, Pentelei-Molnar J, et al. Varicella dendritic keratitis. Invest Ophthalmol. 1974;13:764.
Pavan-Langston D, McCulley JP. Herpes zoster dendritic keratitis. Arch Ophthalmol. 1973;89:25–9.
Uchida Y, Kaneko M, Hayashi K. Varicella dendritic keratitis. Am J Ophthalmol. 1980;89:259.
Magone MT, Nasser RE, Cevallos AV, et al. Chronic recurrent varicella-zoster virus keratitis confirmed by polymerase chain reaction testing. Am J Ophthalmol. 2005;139:1135–6.
deFreitas D, Sato E, Kelly L, et al. Delayed onset varicella keratitis. Cornea. 1992;11:471–4.
Power WJ, Hogan RN, Hu S, et al. Primary varicella-zoster keratitis: diagnosis by polymerase chain reaction. Am J Ophthalmol. 1997;123:252–4.
Robb R. Cataracts acquired following varicella infection. Arch Ophthalmol. 1972;87:352.
Strachman J. Uveitis associated with chicken pox. J Pediatr. 1955;46:327.
Taylor D, Ffytche T. Optic disc pigmentation associated with a field defect following chicken pox. J Pediatr Ophthalmol. 1976;13:80.
Roelandt V, Fayol L, Hugonenq C, et al. Retrobulbar optic nevritis and chicken pox: a case report in a child. Arch Pediatr. 2005;12:278–80.
Gershon AA. The current status of live attenuated varicella vaccine. Arch Virol Suppl. 2001:1–6.
CDC C. Prevention. fDCa: licensure of varicella virus vaccine, live. MMWR. 1995;44:264.
Gershon A. Varicella-zoster virus: prospects for control. Adv Pediatr Infect Dis. 1995;10:93–124.
Gershon AA. Live-attenuated varicella vaccine. Infect Dis Clin North Am. 2001;15:65–81, viii.
Asano Y, Suga S, Yoshikawa T, et al. Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine. Pediatrics. 1994;94:524–6.
Kuter B, Weibel R, Guess H, et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine. 1991;9:643–7.
Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J Med. 2002;347:1909–15.
Arvin AM, Pollard RB, Rasmussen LE, et al. Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest. 1980;65:869–78.
Trannoy E, Berger R, Hollander G, et al. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine. 2000;18:1700–6.
Brunell P, Taylor-Wiedeman J, Geiser C, et al. Risk of herpes zoster in children with leukemia: varicella vaccine compared with history of chickenpox. Pediatrics. 1986;77:53–6.
Hardy I, Gershon A, Sterinberg S, et al. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med. 1991;325:1545–50.
White C. Letter to the Editor. Pediatrics. 1992;89:354.
Matsubara K, Nigami H, Harigaya H, et al. Herpes zoster in a normal child after varicella vaccination. Acta Paediatr Jpn. 1995;37:648–50.
Naseri A, Margolis TP. Varicella zoster virus immune recovery stromal keratitis in a patient with AIDS. Br J Ophthalmol. 2001;85:1390–1.
Gagliardi AM, Andriolo BN, Torloni MR, et al. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2019;2019:11.
Chlibek R, Bayas JM, Collins H, de la Pinta, Rodriguez ML, Ledent E, Mols JF, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. J Infect Dis. 2013;208(12):1953–61.
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96.
Mahalingam R, Wellish M, Lederer D, et al. Quantitation of latent varicella-zoster virus DNA in human trigeminal ganglia by polymerase chain reaction. J Virol. 1993;67:2381–4.
Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340–6.
Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350–4.
Mahalingam R, Cabirac G, Wellish M, et al. In-vitro synthesis of functional varicella zoster and herpes simplex viral thymidine kinase. Virus Genes. 1990;4:105–20.
Mahalingam R, Wellish M, Wolf W, et al. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med. 1990;323:627–31.
Cobo M, Foulks G, Liesegang T, et al. Observations on the natural history of herpes zoster ophthalmicus. Curr Eye Res. 1987;6:195–9.
Donahue J, Choo P, Manson J, et al. The incidence of herpes zoster. Arch Intern Med. 1995;155:1605–9.
Harding S, Lipton J, Wells J. Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement. Br J Ophthalmol. 1987;71:353–8.
Hope-Simpson R. The nature of herpes zoster: a long term study and a new hypothesis. Proc Soc Med. 1965;58:9.
US Department of Health and Human Services, N. External ocular infections and inflammatory disease. Washington, DC: National Eye Institute; 1983. p. 2472.
Weller T. Varicella-zoster virus. History, perspective, and evolving concerns. Neurology. 1995;45(Suppl 8):S9–S10.
Pepose J. The potential impact of varicella vaccine and new antivirals on ocular disease related to varicella-zoster virus. Am J Ophthalmol. 1997;123:243–9.
Insinga RP, Itzler RF, Pellissier JM, et al. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748–53.
Fleming DM, Cross KW, Cobb WA, et al. Gender difference in the incidence of shingles. Epidemiol Infect. 2004;132:1–5.
Hales CM, Harpaz R, Ortega-Sanchez I, et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep. 2014;63:729–31.
Johnson JL, Amzat R, Martin N. Herpes Zoster Ophthalmicus. Prim Care. 2015;42:285–303.
deMoragas J, Kierland R. The outcome of patients with herpes zoster. Arch Dermatol. 1957;75:193.
Liesegang T. Varicella-zoster virus eye disease [Review]. Cornea. 1999;18:511–31.
Severson EA, Baratz KH, Hodge DO, et al. Herpes zoster ophthalmicus in Olmsted county, Minnesota: have systemic antivirals made a difference? Arch Ophthalmol. 2003;121:386–90.
Womack L, Liesegang T. Complications of herpes zoster ophthalmicus. Arch Ophthalmol. 1983;101:42.
Burgoon C Jr, Burgoon J, Baldridge G. The natural history of herpes zoster. JAMA. 1957;164:265.
Edgerton A. Herpes zoster ophthalmicus: report of cases and review of literature. Arch Ophthalmol. 1945;34:40–62.
Scott T. Epidemiology of herpetic infections. Am J Ophthalmol. 1957;43:134.
Schmader K, George LK, Burchett BM, et al. Racial differences in the occurrence of herpes zoster. J Infect Dis. 1995;171:701–4.
Scheie H. Herpes zoster ophthalmicus. Trans Ophthalmol Soc UK. 1970;90:899.
Tunsuriyawong S, Puavilai S. Herpes zoster, clinical course and associated diseases: a 5-year retrospective study at Ramathibodi Hospital. J Med Assoc Thai. 2005;88:678–81.
Buntinx F, Wachana R, Bartholomeeusen S, et al. Is herpes zoster a marker for occult or subsequent malignancy? Br J Gen Pract. 2005;55:102–7.
Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4:26–33.
Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain. 1999;3:335–42.
Miller A. Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology. 1980;30:582.
Gilden D, Varai A, Shtram Y, et al. Varicella-zoster virus DNA in human sensory ganglia. Nature. 1983;306:478–80.
Esiri M, Tomlinson A. Herpes zoster: demonstration of virus in trigeminal nerve and ganglion by immunofluorescence and electron microscopy. J Neurol Sci. 1972;15:35–8.
Bastian F, Rabson A, Yee C, et al. Herpes virus varicella isolated from human dorsal root ganglia. Arch Pathol. 1973;97:331–6.
Dueland A. Latency and reactivation of varicella zoster virus infections. Scand J Infect Dis Suppl. 1996;100:46–50.
Wilson A, Sharp M, Koropchak C, et al. Subclinical varicella-zoster virus viremia, herpes zoster, and T-lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis. 1992;165:119–26.
Gilden D, Dueland A, Devlin M, et al. Varicella-zoster virus reactivation without rash. J Infect Dis. 1992;166(Suppl 1):S30–4.
Weigle KA, Grose C. Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation. J Infect Dis. 1984;149:741–9.
Liesegang T. Corneal complications from herpes zoster ophthalmicus. Ophthalmology. 1985;92:316.
Liesegang T. Herpes zoster ophthalmicus. Int Ophthalmol Clin. 1985;25:77–96.
Pavan-Langston D. In: Pavan-Langston D, editor. Cornea and external disease, in manual of ocular diagnosis and therapy. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2002. p. 67–129.
Starr C, Pavan-Langston D. Varicella-zoster virus: mechanisms of pathogenicity and corneal disease. Ophthalmol Clin North Am. 2002;15:7–15.
Wenkel H, Rummelt C, Rummelt V, et al. Detection of varicella zoster virus DNA and viral antigen in human cornea after herpes zoster ophthalmicus. Cornea. 1993;12:131–7.
Hedges T III, Albert D. The progression of the ocular abnormalities of herpes zoster: histopathologic observations of nine cases. Ophthalmology. 1982;89:169–77.
Nagashima K, Nakazawa M, Endo H. Pathology of the human spinal ganglia in varicella-zoster virus infection. Acta Neuropathol (Berl). 1975;33:105–17.
Ghatak N, Zimmerman H. Spinal ganglion in herpes zoster. Arch Pathol. 1973;95:411–5.
Reske-Nielsen E, Oster S, Pedersen B. Herpes zoster ophthalmicus and the mesencephalic nucleus. A neuropathological study. Acta Pathol Microbiol Immunol Scand. 1986;94:263–9.
Green W, Zimmerman L. Granulomatous reaction of Descemet’s membrane. Am J Ophthalmol. 1967;64:555.
Wenkel H, Rummelt V, Fleckenstein B, et al. Detection of varicella zoster virus DNA and viral antigen in human eyes after herpes zoster ophthalmicus. Ophthalmology. 1998;105:1323–30.
Naumann G, Gass J, Font R. Histopathology of herpes zoster ophthalmicus. Am J Ophthalmol. 1968;65:533.
Zaal MJ, Maudgal PC, Rietveld E, et al. Chronic ocular zoster. Curr Eye Res. 1991;10(Suppl):125–30.
Juel-Jensen B, MacCallum F. In: Juel-Jensen B, editor. Herpes simplex, varicella and zoster: clinical manifestations and treatment. Philadelphia, PA: Lippincott; 1972.
Zaal MJ, Volker-Dieben HJ, D’Amaro J. Prognostic value of Hutchinson’s sign in acute herpes zoster ophthalmicus. Graefes Arch Clin Exp Ophthalmol. 2003;241:187–91.
Watson C, Deck J, Morshead C, et al. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain. 1991;44:105–17.
Liesegang T. Varicella-zoster virus: systemic and ocular features. J Am Acad Dermatol. 1984;11:165.
Pavan-Langston D. In: Cp W, Gershon A, editors. Ophthalmic zoster. Amsterdam: Elsevier Science; 2001. p. 119–29.
Pavan-Langston D. Clinical manifestations and therapy of herpes zoster ophthalmicus. Compr Ophthalmol Update. 2002;3:217–25.
Obata H, Yamagami S, Saito S, et al. A case of acute dacryoadenitis associated with herpes zoster ophthalmicus. Jpn J Ophthalmol. 2003;47:107–9.
Lewis G. Zoster sine herpete. Br Med J. 1958;2:418.
Yamamoto S, Tada R, Shimomura Y, et al. Detecting varicella-zoster virus DNA in iridocyclitis using polymerase chain reaction: a case of zoster sine herpete. Arch Ophthalmol. 1995;113:1358–9.
Yamamoto S, Shimomura Y, Kinoshita S, et al. Differentiating zosteriform herpes simplex from ophthalmic zoster. Arch Ophthalmol. 1994;112:1515–6.
Muller SA, Winkelmann RK. Cutaneous nerve changes in zoster. J Invest Dermatol. 1969;52:71–7.
Forrest W, Kaufman H. Zosteriform herpes simplex. Am J Ophthalmol. 1976;81:86.
Marsh R, Cooper M. Ophthalmic zoster: mucous plaque keratitis. Br J Ophthalmol. 1987;71:725–8.
Piebenga L, Laibson P. Dendritic lesions in herpes zoster ophthalmicus. Arch Ophthalmol. 1973;90:268.
Zaal M, Volker-Dieben H, Wienesen M, et al. Longitudinal analysis of varicella-zoster virus DNA on the ocular surface associated with herpes zoster ophthalmicus. Am J Ophthalmol. 2001;131:25–9.
Pavan-Langston D, Yamamoto S, Dunkel EC. Delayed herpes zoster pseudodendrites. Polymerase chain reaction detection of viral DNA and a role for antiviral therapy. Arch Ophthalmol. 1995;113:1381–5.
Engstrom RE, Holland GN. Chronic herpes zoster virus keratitis associated with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;105:556–9.
Chern KC, Conrad D, Holland GN, et al. Chronic varicella-zoster virus epithelial keratitis in patients with acquired immunodeficiency syndrome. Arch Ophthalmol. 1998;116:1011–7.
Straus S. Clinical and biological differences between recurrent herpes simplex virus and varicella-zoster virus infections. JAMA. 1989;262:3455–8.
Crock G. Clinical syndromes of anterior segment ischaemia. Trans Ophthalmol Soc UK. 1967;87:513.
Marsh R. Ophthalmic herpes zoster. Br J Hosp Med. 1976;15:609–18.
Reijo A, Antti V, Jukka M. Endothelial cell loss in Herpes zoster keratouveitis. Br J Ophthalmol. 1983;67:751.
Liesegang T. In: Tasman W, Haeger E, editors. Varicella zoster viral disease. Philadelphia, PA: Lippincott-Raven; 1991. p. 1–10.
Silverstein BE, Chandler D, Neger R, et al. Disciform keratitis: a case of herpes zoster sine herpete. Am J Ophthalmol. 1997;123:254–5.
Jones D. In: Golden B, editor. Herpes zoster ophthalmicus. Springfield, IL: Charles C. Thomas; 1974. p. 198.
Mondino B, Brown S, Mondzelewski J. Peripheral corneal ulcers with herpes zoster ophthalmicus. Am J Ophthalmol. 1978;86:611.
Mahalingam R, Wellish M, Wolfe W, et al. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med. 1990;323:627–31.
Heigle TJ, Pflugfelder SC. Aqueous tear production in patients with neurotrophic keratitis. Cornea. 1996;15:135–8.
Head H, Campbell A. The pathology of Herpes zoster and its bearing on sensory localization. Brain. 1900;23:379.
Sanjay S, Huang P, Lavanya R. Herpes zoster ophthalmicus. Curr Treat Options Neurol. 2011;13:79–91.
Yamada N, Matsuda R, Morishige N, et al. Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy. Br J Ophthalmol. 2008;92:896–900.
De Monchy I, Labbé A, Pogorzalek N, et al. Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): a case report. J Fr Ophtalmol. 2012;35:187.e1–6.
Marsh RJ, Cooper M. Ocular surgery in ophthalmic zoster. Eye. 1989;3(Pt 3):313–7.
Liesegang TJ. Diagnosis and therapy of herpes zoster ophthalmicus. Ophthalmology. 1991;98:1216–29.
Marsh R, Easty D, Jones B. Iritis and iris atrophy in herpes zoster ophthalmicus. Am J Ophthalmol. 1974;78:255.
Gilden D, Wright R, Schneck S, et al. Zoster sine herpete: a clinical variant. Ann Neurol. 1994;35:530–3.
Kashiwase M, Sakai J, Usui M. Uveitis associated with zoster sine herpete. Diagnosis and clinical findings. Nippon Ganka Gakkai Zasshi (Japanese). 2000;104:97–102.
Nakamura M, Tanabe M, Yamada Y, et al. Zoster sine herpete with bilateral ocular involvement. Am J Ophthalmol. 2000;129:809–10.
Furuta Y, Ohtani F, Mesuda Y, et al. Early diagnosis of zoster sine herpete and antiviral therapy for the treatment of facial palsy. Neurology. 2000;55:708–10.
Eaglstein WH, Katz R, Brown JA. The effect of early corticosteroid therapy on the skin eruptions and pain of herpes zoster. JAMA. 1970;211:1681–3.
Pavan-Langston D. Varicella-zoster ophthalmicus. In: Pavan-Langston D, editor. Ocular viral disease, International Ophthalmology Clinics. Boston: Little Brown; 1975. p. 171–85.
Marsh R, Dudley B, Kelly V. External ocular motor palsies in ophthalmic zoster: a review. Br J Ophthalmol. 1977;61:677–82.
Archambault P, Wise JS, Rosen J, et al. Herpes zoster ophthalmoplegia. Report of six cases. J Clin Neuroophthalmol. 1988;8:185–93.
Shin HM, Lew H, Yun YS. A case of complete ophthalmoplegia in herpes zoster ophthalmicus. Korean J Ophthalmol. 2005;19:302–4.
Al-Abdulla N, Rismondo V, Minkowski J, et al. Herpes zoster vasculitis presenting as giant cell arteritis with bilateral internuclear ophthalmoplegia. Am J Ophthalmol. 2002;134:912–4.
Hallas P. Pupillary paresis. A rare complication of varicella zoster eye infection. Ugeskr Laeger (Danish). 2001;163:5835–6.
Pandey PK, Chaudhuri Z, Sharma P. Extraocular muscle and facial paresis in herpes zoster ophthalmicus. J Pediatr Ophthalmol Strabismus. 2001;38:363–6.
Pandey PK, Garg D, Bhatia A, et al. Horner’s syndrome and sixth nerve palsy due to herpes zoster ophthalmicus arteritis. Eye. 2005;19:224–6.
Sodhi P, Goel J. Presentations of cranial nerve involvement in two patients with Herpes zoster ophthalmicus. J Commun Dis. 2001;33:130–5.
Engstrom R, Holland G, Margolis T, et al. The progressive outer retinal necrosis syndrome. A variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology. 1994;101:1488–502.
Oueghlani E, Baglivo E, Durakovic O, et al. Varicella-zoster virus retinitis: successful evolution with a combination of antiviral therapies. Klin Monbl Augenheilkd. 2005;222:264–6.
Scott FT, Leedham-Green ME, Barrett-Muir WY, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol. 2003;70(Suppl 1):S24–30.
Haanpaa M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage. 2000;20:50–8.
Zaal M, Volker-Dieben H, D’Amaro J. Risk and prognostic factors of postherpetic neuralgia and focal sensory denervation: a prospective evaluation in acute herpes zoster ophthalmicus. Clin J Pain. 2000;16:345–51.
Oaklander AL, Bowsher D, Galer B, et al. Herpes zoster itch: preliminary epidemiologic data. J Pain. 2003;4:338–43.
Opstelten W, Mauritz JW, de Wit NJ, et al. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database. Fam Pract. 2002;19:471–5.
Dworkin RH, Boon RJ, Griffin DR, et al. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis. 1998;178(Suppl 1):S76–80.
Harding S, Lipton J, Wells J, et al. Relief of acute pain in herpes zoster ophthalmicus by stellate ganglion block. Br Med J. 1986;292:1428.
Liesegang TJ. Ophthalmic herpes zoster: diagnosis and antiviral therapy. Geriatrics. 1991;46:64–6, 69–71.
Watson CP, Oaklander AL, Deck J. In: Watson CP, Gershon AA, editors. The neuropathology of herpes zoster with particular reference to postherpetic neuralgia and its pathogenesis. Amsterdam: Elsevier-Science; 2001. p. 168–82.
Oaklander AL, Romans K, Horasek S, et al. Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Ann Neurol. 1998;44:789–95.
Pappagallo M, Oaklander AL, Quatrano-Piacentini AL, et al. Heterogenous patterns of sensory dysfunction in postherpetic neuralgia suggest multiple pathophysiologic mechanisms. Anesthesiology. 2000;92:691–8.
Gilden DH, Cohrs RJ, Hayward AR, et al. Chronic varicella-zoster virus ganglionitis – a possible cause of postherpetic neuralgia. J Neurovirol. 2003;9:404–7.
Gilden DH, Cohrs RJ, Mahalingam R. VZV vasculopathy and postherpetic neuralgia: progress and perspective on antiviral therapy. Neurology. 2005;64:21–5.
Bennett G. Hypotheses on the pathogenesis of herpes zoster-associated pain. Ann Neurol. 1994;35(Suppl):S38–41.
Watson CP. Management issues of neuropathic trigeminal pain from a medical perspective. J Orofac Pain. 2004;18:366–73.
Watson CP, Morshead C, Van der Kooy D, et al. Post-herpetic neuralgia: post-mortem analysis of a case. Pain. 1988;34:129–38.
Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356–63.
Cole E, Meisler D, Calabrese D, et al. Herpes zoster ophthalmicus and acquired immune deficiency syndrome. Arch Ophthalmol. 1984;102:1027.
Seiff S, Margolis T, Graham S, et al. Use of intravenous acyclovir for treatment of herpes zoster ophthalmicus in patients at risk for AIDS. Ann Ophthalmol. 1988;20:480.
Freidmann-Kein A, LaFleur F, Gendler E, et al. Herpes zoster: a possible clinical sign for development of acquired immune deficiency syndrome in high risk individuals. J Am Acad Dermatol. 1986;14:1023–8.
Sandor E, Millman A, Croxson S, et al. Herpes zoster ophthalmicus in patients at risk for the acquired immune deficiency syndrome (AIDS). Am J Ophthalmol. 1986;101:153.
Sandor E, Schnall C, Croxson T, et al. Herpes zoster ophthalmicus in young patients and its correlation with HTLV-III sensitivity. ARVO Abstracts. 1987;28:46.
Pepose JS. External ocular herpesvirus infections in immunodeficiency. Curr Eye Res. 1991;10(Suppl):87–95.
Gebo KA, Kalyani R, Moore RD, et al. The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr. 2005;40:169–74.
Thomson KJ, Hart DP, Banerjee L, et al. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:1065–9.
McGill J, Chapman C. Comparison of topical acyclovir with steroids in the treatment of herpes zoster keratouveitis. Br J Ophthalmol. 1983;67:746.
Borruat F, Buechi E, Piguet F, et al. Prevention of ocular complications of herpes zoster ophthalmicus by adequate treatment with acyclovir. Klin Monbl Augenheilkd. 1991;198:358–60.
Cobo L, Foulks G, Liesegang T, et al. Oral acyclovir in the therapy of acute herpes zoster ophthalmicus: an interim report. Ophthalmology. 1985;92:1574.
Cobo L, Foulks G, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986;93:763.
Harding S, Porter S. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res. 1991;10:177–82.
Hoang-Xuan T, Buchi ER, Herbort CP, et al. Oral acyclovir for herpes zoster ophthalmicus. Ophthalmology. 1992;99:1062–71.
Aylward G, Claoue C, Marsh R, et al. Influence of oral acyclovir on ocular complications of herpes zoster ophthalmicus. Eye. 1994;8:70–4.
Lilie HM, Wassilew S. The role of antivirals in the management of neuropathic pain in the older patient with herpes zoster. Drugs Aging. 2003;20:561–70.
McGill J, White J. Acyclovir and post-herpetic neuralgia and ocular involvement. Br Med J. 1994;309:1124–8.
Manka R. Exogenous lactase in the treatment of oral acyclovir intolerance. Am J Ophthalmol. 1989;108:733.
Gross G, Schofer H, Wassilew S, et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol. 2003;26:277–89; discussion 291–273.
Dias C, Nashed Y, Atluri H, et al. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: an evaluation using ocular microdialysis and LC-MS. Curr Eye Res. 2002;25:243–52.
Colin J, Prisant O, Cochener B, et al. A double blind randomized trial to compare the efficacy and safety of valaciclovir and acyclovir for treatment of herpes zoster ophthalmicus. Ophthalmology. 2000;107:1507–11.
Fiddian A. Antiviral drugs in development for herpes zoster. Scand J Infect Dis Suppl. 1996;100:51–4.
Tyring S, Beutner K, Tucker B, et al. Antiviral therapy for herpes zoster: randomized controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med. 2000;9:863–9.
Tyring S, Douglas JJ, Corey L, et al. A randomized, placebo-controlled comparison of oral valaciclovir and acyclovir in immunocompetent patients with recurrent genital herpes infections. Arch Dermatol. 1998;134:185–91.
Colin J, Prisant O, Cochener B, et al. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology. 2000;107:1507–11.
Lo DM, Jeng BH, Gillespie C, et al. Current practice patterns and opinions on the management of recent-onset or Chronic Herpes Zoster Ophthalmicus of Zoster Eye Disease Study Investigators. Cornea. 2019;38:13–7.
Boyd M, Safrin S, Kern E. Penciclovir: a review of spectrum of activity, selectivity, and cross-resistance pattern. Antivir Chem Chemother. 1993;4(Suppl 1):25–36.
Goldani LZ. Treatment of severe infectious mononucleosis with famciclovir. J Infect. 2002;44:92–3.
Vere Hodge R, Cheng Y-C. The mode of action of penciclovir. Antiviral Agents Chemother. 1993;4(Suppl 1):13–24.
deGreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents. 1994;4:241–6.
deGreef H. Famciclovir, a new oral antiviral drug: its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents. 1995;4:241–6.
Gheeraert P, Group. Efficacy and safety of famciclovir in the treatment of uncomplicated herpes zoster. Program and Abstracts, 32nd ICAAC. Washington, DC: American Society for Microbiology; 1992. p. 1108.
Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother. 1994;38:2454–7.
Tyring S. Efficacy of famciclovir in the treatment of herpes zoster. Semin Dermatol. 1996;15(2 Suppl 1):27–31.
Tyring S. Famiciclovir therapy (Famvir†) for herpes simplex and herpes zoster infections. Skin Therapy Lett. 2001;6:1–2,5.
Tyring S, Belanger R, Bezwoda W, et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest. 2001;19:13–22.
Tyring SK, Diaz-Mitoma F, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: the combined data from two randomized controlled trials. J Cutan Med Surg. 2003;7:449–54.
Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol. 2001;85:576–81.
Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res. 2003;59:57–60.
Whitley R, Weiss H, Gnann JJ, et al. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med. 1996;125:376–83.
Wood M, Johnson R, McKendrick M, et al. A randomized trial of acyclovir for 7 days and 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med. 1994;330:896–900.
Dworkin RH, Johnson RW, Breuer J, et al. Guidelines for the management of Herpes Zoster. Clin Infect Dis. 2007;44:S1–S26.
Merselis J, Kaye D, Hook E. Disseminated herpes zoster. Arch Intern Med. 1961;113:679.
Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2:164.
Argoff CE. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain. 2002;18:S177–81.
Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage. 2004;28:396–411.
Levin J, Gordon N, Smith R, et al. Desipramine enhances opiate postoperative analgesia. Pain. 1986;27:45.
Urban B, France R, Steinberger E, et al. Longer term use of narcotic/antidepressant medication in the management of phantom limb pain. Pain. 1986;24:191.
Hardy D. Relief of pain in acute herpes zoster by nerve blocks and possible prevention of post-herpetic neuralgia. Can J Anaesth. 2005;52:186–90.
Wasner G, Kleinert A, Binder A, et al. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol. 2005;252:677–86.
Bowsher D. The effects of preemptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage. 1997;13:327–31.
Satterthwaite J, Tollison C, Kriegel M. Use of tricyclic antidepressants for the treatment of intractable pain. Compr Ther. 1990;16:10.
Watson C, Evans R, Reed K. Amitriptyline vs placebo in post-herpetic neuralgia. Neurology. 1982;32:671.
Watson C, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. 1998;51:1166–71.
Bowsher D. Factors influencing the features of postherpetic neuralgia and outcome when treated with tricyclics. Eur J Pain. 2003;7:1–7.
Hurtig H. Fluphenazine and post-herpetic neuralgia. JAMA. 1990;263:2750.
Murphy T. Post-herpetic neuralgia. JAMA. 1989;262:3478–81.
Dworkin R, Schmader K. Treatment and prevention of postherpetic neuralgia. Review. Clin Infect Dis. 2003;36:877–82.
Galen B. Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology. 1995;45(Suppl 9):S17–25.
Panlilio LM, Christo PJ, Raja SN. Current management of postherpetic neuralgia. Neurologist. 2002;8:339–50.
Berger A, Dukes E, McCarberg B, et al. Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia. Clin Ther. 2003;25:2809–21.
Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233–49.
US Pharmacopeia – Gabapentin. Greenwood Village, CO: Thomson Micromedex; 2005.
Stacey BR, Glanzman RL. Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. Clin Ther. 2003;25:2597–608.
Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837–42.
Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. Drugs. 2005;65:111–8; discussion 119–120.
Hadj Tahar A. Pregabalin for peripheral neuropathic pain. Issues Emerg Health Technol. 2005:1–4.
Dworkin R, Corbin A, Young JJ, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274–83.
Argoff CE. Targeted topical peripheral analgesics in the management of pain. Curr Pain Headache Rep. 2003;7:34–8.
Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin. 2004;20(Suppl 2):S21–8.
Gain P, Thuret G, Chiquet C, et al. Frontal and nasal nerve blocks in the treatment of severe pain in acute ophthalmic zoster. Anesth Analg. 2002;95:503.
Gain P, Thuret G, Chiquet C, et al. Facial anesthetic blocks in the treatment of acute pain during ophthalmic zoster. J Fr Ophtalmol (French). 2003;26:7–14.
Borodic GE, Acquadro MA. The use of botulinum toxin for the treatment of chronic facial pain. J Pain. 2002;3:21–7.
Sangwan VS, Matalia HP, Vemuganti GK, et al. Early results of penetrating keratoplasty after cultivated limbal epithelium transplantation. Arch Ophthalmol. 2005;123:334–40.
Reed J, Joyner S, Knauer W III. Penetrating keratoplasty for Herpes zoster keratopathy. Am J Ophthalmol. 1989;107:257.
Pavan-Langston D, Dohlman CH. Boston keratoprosthesis treatment of herpes zoster neurotrophic keratopathy. Am J Ophthalmol. 2007;115(2 Suppl):S21–3.
Aaberg T, O’Brien W. Expanding ophthalmologic recognition of Epstein-Barr virus infections. Am J Ophthalmol. 1987;104:420.
Henle G, Henle W. Observations on childhood infections with the Epstein-Barr virus. J Infect Dis. 1970;121:303–10.
Ogawa G, Vastine D. In: Tabbara K, Hyndiuk R, editors. Nonherpetic viral keratitis. Boston, MA: Little, Brown; 1996. p. 401–22.
Johanssen E, Schooley R, Kaye K. In: Mandell G, Bennett J, Dolin R, editors. Epstein-Barr virus. Philadelphia, PA: Elsevier, Churchill Livingstone; 2005. p. 1801–20.
McCallum R. Infectious mononucleosis and the Epstein-Barr virus. J Infect Dis. 1970;121:347.
Stagno S, Whitley R. Herpes virus infections of pregnancy. Parts I and II: Cytomegalovirus and Epstein Barr virus infections. N Engl J Med. 1985;313(1270–1275):1327–232.
Henle W, Henle G. Serodiagnosis of infectious mononucleosis. Resident Staff Phys. 1981;27:37.
Matoba A, McCulley J. In: Darrell R, editor. Epstein-Barr virus and its ocular manifestations. Philadelphia, PA: Lea & Febiger; 1985.
Matoba A, Wilhelmus K, Jones D. Epstein-Barr viral stromal keratitis. Ophthalmology. 1986;93:746–50.
Niederman J, Evans A, Subrahmanyan L, et al. Prevalence, incidence and persistence of EB virus antibody in young adults. N Engl J Med. 1970;272:361.
Meisler D, Bosworth D, Krachmer J. Ocular infectious mononucleosis manifested as Parinaud’s oculoglandular syndrome. Am J Ophthalmol. 1981;92:722.
Wong K, D’Amico D, Hedges TI, et al. Ocular involvement associated with chronic Epstein-Barr virus disease. Arch Ophthalmol. 1987;105:788.
Kanafani ZA, Bashur Z, Kanj SS. Acute Epstein-Barr virus infection causing bilateral conjunctival hemorrhages. South Med J. 2005;98:390–1.
Woog JJ, Kim YD, Yeatts RP, et al. Natural killer/T-cell lymphoma with ocular and adnexal involvement. Ophthalmology. 2006;113:140–7.
Merayo-Lloves J, Baltalzis S, Foster CS. Epstein-Barr virus dacryoadenitis resulting in keratoconjunctivitis sicca in a child. Am J Ophthalmol. 2001;132:922–3.
Pflugfelder S, Crouse C, Atherton S. Ophthalmic manifestations of Epstein-Barr virus infection. Int Ophthalmol Clin. 1993;33:95–101.
Pflugfelder S, Huang C, Crouse C. Epstein-Barr virus keratitis after a facial chemical peel. Am J Ophthalmol. 1990;110:571.
Pflugfelder S, Tseng S, Pepose J, et al. Epstein-Barr virus infection and immunologic dysfunction in patients with aqueous tear deficiency. Ophthalmology. 1990;97:313.
Pinnolis M, McCulley J. Nummular keratitis associated with infectious mononucleosis. Am J Ophthalmol. 1980;89:791.
Salzberger B, Hartmann P, Hanses F, et al. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy. Infection. 2005;33:345–9.
Nankervis G, Kumar M. Diseases produced by cytomegaloviruses. Med Clin North Am. 1978;62:1021.
Onorato I, Morens D, Martone W, et al. Epidemiology of cytomegalovirus infections. Recommendation for prevention and control. Rev Infect Dis. 1985;7:479.
Crumpacker C, Wadwha S. In: Mandell G, Bennett J, Dolin R, editors. Cytomegalovirus. Philadelphia, PA: Elsevier, Churchill Livingstone; 2005. p. 1786–800.
Brody JM, Butrus SI, Laby DM, et al. Anterior segment findings in AIDS patients with cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol. 1995;233:374–6.
Garau J, Kabins S, DeNassquo S, et al. Spontaneous cytomegalovirus mononucleosis with conjunctivitis. Arch Intern Med. 1977;137:1631.
Brown HH, Glasgow BJ, Holland GN, et al. Cytomegalovirus infection of the conjunctiva in AIDS. Am J Ophthalmol. 1988;106:102–4.
Ohashi Y, Kinoshita S, Mano T, et al. Idiopathic corneal endotheliopathy. A report of two cases. Arch Ophthalmol. 1985;103:1666–8.
Koizumi N, Yamasaki K, Kawasaki S, et al. Cytomegalovirus in aqueous humor from an eye with corneal endotheliitis. Am J Ophthalmol. 2006;141:564–5.
Koizumi N, Inatomi T, Suzuki T, et al. Clinical features and management of cytomegalovirus corneal endotheliitis: analysis of 106 cases from the Japan corneal endotheliitis study. Br J Ophthalmol. 2015;99:54–8.
Kobayashi R, Hashida N, Soma T, et al. Clinical findings of anterior segment spectral domain optical coherence tomography images in cytomegalovirus corneal endotheliitis. Cornea. 2017;36:411–4.
Su CC, Wang IJ, Chen WL, et al. Topical ganciclovir treatment in patients with cytomegalovirus endotheliitis receiving penetrating keratoplasty. Clin Exp Ophthalmol. 2013;41:339–47.
Weller T. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. N Engl J Med. 1971;285:203.
Holland E, Bennett S, Brannian R, et al. The risk of cytomegalovirus transmission by penetrating keratoplasty. Am J Ophthalmol. 1988;105:357.
Mietz H, Aisenbrey S, Ulrich Bartz-Schmidt K, et al. Ganciclovir for the treatment of anterior uveitis. Graefes Arch Clin Exp Ophthalmol. 2000;238:905–9.
Baum S. In: Mandell G, Bennett J, Dolin R, editors. Adenovirus. Philadelphia, PA: Elsevier, Churchill Livingstone; 2005. p. 1835–40.
Duke-Elder S. In: Duke-Elder S, editor. The adenoviruses. St Louis, MO: CV Mosby; 1965. p. 348.
Gordon Y. In: Smolin G, Thoft R, editors. Adenovirus and other nonherpetic viral diseases. Boston, MA: Little, Brown; 1994. p. 215–28.
Kinchington PR, Romanowski EG, Jerold Gordon Y. Prospects for adenovirus antivirals. J Antimicrob Chemother. 2005;55:424–9.
Guyer B, O’Day D, Hierholzer J, et al. Epidemic keratoconjunctivitis: types 8 and 19. J Infect Dis. 1975;132:142.
Tullo A. In: Easty D, editor. The adenoviruses. Chicago, IL: Year Book Medical; 1985. p. 257–70.
Azar M, Dhaliwal K, Bower K, et al. Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis. Am J Ophthalmol. 1996;121:711–2.
Gordon YJ, Gordon RY, Romanowski E, et al. Prolonged recovery of desiccated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces in vitro. Ophthalmology. 1993;100:1835–9.
Sprague JB, et al. Epidemic keratoconjunctivitis: a severe industrial outbreak due to adenovirus type 8. N Engl J Med. 1973;289:1341–6.
Laibson P, Ortolan G, Dupre-Strachan S. Community and hospital outbreak of epidemic keratoconjunctivitis. Arch Ophthalmol. 1968;80:467.
O’Day D, Guyer B, Hierholzer J, et al. Clinical and laboratory evaluation of epidemic keratoconjunctivitis due to adenoviruses type 8 and 19. Am J Ophthalmol. 1976;81:207.
Kowalski RP, Sundar-Raj CV, Romanowski EG, et al. The disinfection of contact lenses contaminated with adenovirus. Am J Ophthalmol. 2001;132:777–9.
Chodosh J, Miller D, Stroop W, et al. Adenoviral epithelial keratitis. Cornea. 1995;14(2):167–74.
Uchio E, Takeuchi S, Itoh N, et al. Clinical and epidemiological features of acute follicular conjunctivitis with special reference to that caused by herpes simplex virus type 1. Br J Ophthalmol. 2000;84:968–72.
Waring GI, Laibson P, Satz J, et al. Use of vidarabine in epidemic keratoconjunctivitis due to adenovirus types 3, 7, 8 and 19. Am J Ophthalmol. 1976;82:781–5.
Dawson C, Darrell D. Infections due to adenovirus type 8 in the United States. I. An outbreak of epidemic keratoconjunctivitis originating in physician’s office. N Engl J Med. 1963;268:1031.
Dawson C, Hanna L, Togni B. Adenovirus type 8 infections in the United States. IV. Observations on the pathogenesis of lesions in severe eye disease. Arch Ophthalmol. 1972;87:258.
Dawson C, Hanna M, Wood T, et al. Adenovirus type 8 keratoconjunctivitis in the United States. III. Epidemiologic, clinical and microbiologic features. Am J Ophthalmol. 1970;69:473.
Laibson P, Dhiri S, Oconer J, et al. Corneal infiltrates in epidemic keratoconjunctivitis: response to double blind corticosteroid therapy. Arch Ophthalmol. 1970;84:36.
Murrah W. Epidemic keratoconjunctivitis. Ann Ophthalmol. 1988;20:36.
Laibson P. Adenoviral keratoconjunctivitis. In: Pavan-Langston D, editor. Ocular Viral Disease, Int Ophthalmol Clin, Ed, vol. 15. Boston, MA: Little Brown; 1975. p. 187–201.
Boniuk M, Philips C, Friedman J, et al. Chronic adenovirus type 2 keratitis in man. N Engl J Med. 1965;273:924.
Darougar S, Quinlan J, Gibson J, et al. Epidemic keratoconjunctivitis and chronic papillary conjunctivitis in London due to adenovirus type 19. Br J Ophthalmol. 1977;61:76.
Pettit T, Holland G. Chronic keratoconjunctivitis associated with ocular adenovirus infection. Am J Ophthalmol. 1979;88:748.
Hecht S, Hanna L, Sery T, et al. Treatment of epidemic keratoconjunctivitis with idoxuridine (IUDR). Arch Ophthalmol. 1965;73:49.
Pavan-Langston D, Dohlman C. A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis. Am J Ophthalmol. 1972;74:81.
Gordon Y, Romanowski E, Araullo-Cruz T. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the rabbit ocular model. Cornea. 1994;13(6):516–20.
Romanowski E, Gordon Y, Araullo-Cruz T, et al. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model. Invest Ophthalmol Vis Sci. 2001;42:1812–5.
Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res. 2001;52:275–80.
Romanowski EG, Gordon YJ. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci. 2000;41:460–3.
Romanowski EG, Roba LA, Wiley L, et al. The effects of corticosteroids of adenoviral replication. Arch Ophthalmol. 1996;114:581–5.
Romanowski EG, Yates KA, Gordon YJ. Topical corticosteroids of limited potency promote adenovirus replication in the Ad5/NZW rabbit ocular model. Cornea. 2002;21:289–91.
Chou R, Huffman LH, Fu R, et al. Screening for HIV: a review of the evidence for the US. Preventive Services Task Force. Ann Intern Med. 2005;143:55–73.
CDC, for Disease Control and Prevention. The global HIV and AIDS epidemic. MMWR. 2001;50:434–9.
CDC, ACoIP. Surveillance of health care workers with HIV/AIDS. 2002. http://www.cdc.gov/hiv/pubs/facts/hchsurv.htm. Accessed 13 Sept 2002.
Walensky R, Losina E, Steger-Craven K, et al. Identifying undiagnosed human immunodeficiency virus. Arch Intern Med. 2002;162:887–92.
Karon JM, Fleming PL, Steketee RW, et al. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health. 2001;91:1060–8.
Guex-Crosier Y. Diagnosis and treatment of ocular viral infections in AIDS patients. Rev Med Suisse Romande. 1998;118:941–7.
Meyer D. Eye signs that alert the clinician to a diagnosis of AIDS. SADJ. 2005;60:386–7.
Dunn J, Holland G. In: Tabbara K, Hyndiuk R, editors. Human immunodeficiency virus infection and AIDS. Boston, MA: Little, Brown; 1996. p. 625–44.
Chan CC, Zhang M. Ocular manifestations in HIV/AIDS. Zhonghua Yan Ke Za Zhi. 2005;41:563–71.
Kahraman G, Krepler K, Franz C, et al. Seven years of HAART impact on ophthalmic management of HIV-infected patients. Ocul Immunol Inflamm. 2005;13:213–8.
Grossniklaus H, Frank K, Tomsak R. Cytomegalovirus retinitis and optic neuritis in acquired immune deficiency syndrome. Ophthalmology. 1987;94:1601.
Mesaric B, Lisic M, Kniewald T, et al. Ocular manifestations in patients with human immunodeficiency virus infection before and after the introduction of highly active antiretroviral therapy. Lijec Vjesn. 2005;127:123–8.
Melbye M, Grossman RJ, Goedert JJ, et al. Risk of AIDS after herpes zoster. Lancet. 1987;1:728–30.
Sterling T, Chaisson R. In: Mandell G, Bennett J, Dolin R, editors. General clinical manifestations of human immunodeficiency virus infection (including acute retroviral syndrome, and oral, cutaneous, renal, ocular, and cardiac diseases). Philadelphia, PA: Elsevier, Churchill Livingstone; 2005. p. 1546–66.
Pepose J, Holland G, Nestor M, et al. Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease. Ophthalmology. 1985;92:472.
Pflugfelder S, Saulson R, Ullman S. Peripheral corneal ulceration in a patient with AIDS-related complex. Am J Ophthalmol. 1987;104:542.
Dugel P, Gill P, Frangieh G, et al. Ocular adnexal Kaposi’s sarcoma in acquired immunodeficiency syndrome. Am J Ophthalmol. 1990;110:500.
Dugel P, Gill P, Frangieh G, et al. Particles resembling retrovirus in conjunctival Kaposi’s sarcoma. Am J Ophthalmol. 1990;110:86.
Holland GN, Gottlieb MS, Yee RD, et al. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol. 1982;93:393–402.
Zuccati G, Tiradritti L, Mastrolorenzo A, et al. AIDS-related Kaposi’s sarcoma of the eye. Int J STD AIDS. 1991;2:136–7.
Sissolak G, Mayaud P. AIDS-related Kaposi’s sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health. 2005;10:981–92.
Nakamura S, Salahuddin S, Biberfeld P, et al. Kaposi’s sarcoma cells. Long term culture with growth factor from retrovirus-infected C.D. #4 +T. Science. 1989;242:426.
Cantrill H, Henry K, Jackson B, et al. Recovery of human immunodeficiency virus from ocular tissues in patients with acquired immune deficiency syndrome. Ophthalmology. 1988;95:1458.
Conway M, Insler M. Identification and incidence of human immunodeficiency virus antibodies and hepatitis B virus antigens in corneal donors. Ophthalmology. 1988;95:1463.
Doro S, Navia B, Kahn A, et al. Confirmation of HTLV-III virus in cornea. Am J Ophthalmol. 1990;101:390.
Fujikawa L, Salahuddin S, Dharam A, et al. HTLV-III in the tears of AIDS patients. Ophthalmology. 1986;93:1479.
O’Day D. The risk posed by HTLV-III-infected corneal donor tissue. Am J Ophthalmol. 1986;101:246.
Salahuddin S, Palestine A, Hecke R, et al. Isolation of the human T-cell leukemia/lymphotropic virus type III from the cornea. Am J Ophthalmol. 1986;101:149.
Damon I. In: Mandell G, Bennett J, Dolin R, editors. Orthopoxviruses Vaccinia (Smallpox Vaccine), Variola (Smallpox), Monkeypox, Cowpox. Philadelphia, PA: Elsevier, Churchill Livingstone; 2005. p. 1742–52.
Damon I. In: Mandell G, Bennett J, Dolin R, editors. Other Poxviruses that infect humans: parapoxvirus, molluscum contagiosum, and tanapox. Philadelphia, PA: Elsevier, Churchill Livingstone; 2005. p. 1753–6.
Pepose J, Esposito J. In: Pepose J, Holland G, Wilhelmus K, editors. Molluscum contagiosum, orf, and vaccinia. St Louis, MO: Mosby; 1996. p. 846–56.
Hanson D, Diven D. Molluscum contagiosum. Review. Dermatol Online J. 2003;9:2.
Ingraham H, Schoenleber D. Epibulbar molluscum contagiosum. Am J Ophthalmol. 1998;125:394–6.
North R. In: Pavan-Langston D, editor. Presumptive viral keratoconjunctivitis, mononucleosis and the oncogenic viruses. Boston, MA: Little, Brown; 1975. p. 211.
Gonnering R, Kronish J. Treatment of periorbital molluscum contagiosum by incision and curettage. Ophthalmol Surg. 1988;19:325–9.
Hancox JG, Jackson J, McCagh S. Treatment of molluscum contagiosum with the pulsed dye laser over a 28-month period. Cutis. 2003;71:414–6.
De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol Sci. 2002;23:456–8.
Neyts J, ED C. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res. 2003;57:25–33.
Maldarelli F. In: Mandell G, Bennett J, Dolin R, editors. Diagnosis of human immunodeficiency virus infection. Philadelphia, PA: Elsevier, Churchill Livingstone; 2005. p. 1506–26.
Kilby J, Eron J. Novel therapies based on mechanisms of HIV-1 cell entry. N Engl J Med. 2003;348:2228–38.
Cono J, Casey CG, Bell DM. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep. 2003;52:1–28.
Henderson D, Inglesley T, Bartlett J, et al. Smallpox as a biological weapon: medical and public health management (consensus statement). JAMA. 1999;281:2127–37.
Maki DG. National preparedness for biological warfare and bioterrorism: smallpox and the ophthalmologist. Arch Ophthalmol. 2003;121:710–1.
Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices. CDC MMWR, 50: No. RR-2001;10:1–22.
Brauner S, Pavan-Langston D. In: Miller J, editor. Small pox, vaccinia, and the eye. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006.
CDC, CfDCaP. Smallpox fact sheet, smallpox overview, 2002. http://www.cdc.gov/smallpox.
Lane JM, Ruben FL, Neff JM, et al. Complications of smallpox vaccination, 1968. N Engl J Med. 1969;281:1201–8.
Ruben F, Lane J. Ocular vaccinia: epidemiologic analysis of 348 cases. Arch Ophthalmol. 1970;84:45–51.
Ellis P, Winograd L. Current concepts of ocular vaccinia. Trans Proc Coast Otoophthalmol Soc. 1963;44:141–8.
Jones B, Al-Hussaini M. Therapeutic considerations in ocular vaccinia. Trans Ophthalmol Soc UK. 1964;83:613–31.
Pepose JS, Margolis TP, Pavan-Langston D. Ocular complications of smallpox vaccination. Am J Ophthalmol. 2003;136:343–52.
CDC, ACoIP. Summary of October 2002 ACIP Smallpox Vaccination Recommendations. Atlanta: Centers for Disease Control and Prevention; 2002. http://www.bt.cdc.gov/agent/smallpox/vaccination/acip-recs-oct2002.asp.
Kempe C. Studies on smallpox and complications of smallpox vaccination. Pediatrics. 1960:76–89.
Elion G, Rideout J, de Miranda P, et al. Biological activities of some purine arabinosides. Ann N Y Acad Sci. 1975;255:468–80.
Elion GB, Furman PA, Fyfe JA, et al. The selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Reproduced from Proc Natl Acad Sci USA 1977; 74:5716–5720. Rev Med Virol. 1999;9:147–52; discussion 152–143.
Hyndiuk R, Seideman S, Leibsohn J. Treatment of vaccinial keratitis with vidarabine. Arch Ophthalmol. 1976;94:1363.
Hyndiuk R, Seideman S, Leibsohn J. Treatment of vaccinial keratitis with trifluorothymidine. Arch Ophthalmol. 1976;94:1976.
Jack M, Sorenson R. Vaccinial keratitis treated with IDU. Arch Ophthalmol. 1963;69:730–2.
Snoeck R, Holy A, Deworlf-Peeters C, et al. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob Agents Chemother. 2002;46:3356–61.
Breman J, Henderson D. Diagnosis and management of smallpox. N Engl J Med. 2002;346:1300–8.
Chirambo MC, Benezra D. Causes of blindness among students in blind school institutions in a developing country. Br J Ophthalmol. 1976;60:665–8.
Koplan J, Hicks J. Smallpox and vaccinia in the United States – 1972. J Infect Dis. 1974;129:224.
Bonnez W, Reichman R. In: Mandell G, Bennett J, Dolin R, editors. Papillomaviruses. Philadelphia, PA: Elsevier, Churchill Livingstone; 2005. p. 1841–50.
Scott I, Karp C, Nuovo G. Human papillomavirus 16 and 18 expression in conjunctival intraepithelial neoplasia. Ophthalmology. 2002;109:542–7.
Prasad C. Pathobiology of human papilloma viruses. Clin Lab Med. 1995;15(3):685–704.
Andrei G, Snoeck R, Schols D, et al. Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12:397–408.
Simonart T, Boelaert JR, Mosselmans R, et al. Antiproliferative and apoptotic effects of iron chelators on human cervical carcinoma cells. Gynecol Oncol. 2002;85:95–102.
Raley JC, Followwill KA, Zimet GD, et al. Gynecologists’ attitudes regarding human papilloma virus vaccination: a survey of Fellows of the American College of Obstetricians and Gynecologists. Infect Dis Obstet Gynecol. 2004;12:127–33.
Sowjanya AP, Jain M, Poli UR, et al. Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. BMC Infect Dis. 2005;5:116.
Greyson M. In: Greyson M, editor. Acute and chronic follicular conjunctivitis. St Louis, MO: Mosby; 1983. p. 114.
Haltier M, Tarkkanen A, Vaheri A, et al. Measles retinopathy: measles retinopathy during immunosuppression. Br J Ophthalmol. 1978;62:356.
Meyer R, Sullivan J, Oh J. Mumps conjunctivitis. Am J Ophthalmol. 1974;78:1022.
Mickatavatge R, Amadur J. A case report of mumps keratitis. Arch Ophthalmol. 1963;69:758.
Riffenburgh R. Ocular manifestations of mumps. Arch Ophthalmol. 1961;66:739.
Kayikcioglu O, Kir E, Soyler M, et al. Ocular findings in a measles epidemic among young adults. Ocul Immunol Inflamm. 2000;8:59–62.
Toker MI, Erdem H, Erdogan H, et al. The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial. Am J Ophthalmol. 2006;141:902–5.
Baum J. Hemorrhagic conjunctivitis: a new type of epidemic viral keratoconjunctivitis. Surv Ophthalmol. 1973;17:489.
Mitsui Y, Kajima M, Matsumura K, et al. Hemorrhagic conjunctivitis: a new type of epidemic viral keratoconjunctivitis. Jpn J Ophthalmol. 1972;16:33.
Rosa R, Alfonso E. In: Pepose J, Holland G, Wilhelmus K, editors. Enterovirus keratoconjunctivitis. St Louis, MO: Mosby; 1996. p. 895–904.
Uchio E, Yamazaki K, Aoki K, et al. Detection of enterovirus 70 by polymerase chain reaction in acute hemorrhagic conjunctivitis. Am J Ophthalmol. 1996;122:273–5.
Whitcher J, Schmidt N, Malbrouk R, et al. Acute hemorrhagic conjunctivitis in Tunisia. Arch Ophthalmol. 1975;94:51.
Langford MP, Orillac R, Chen D, et al. Systemic and ocular antibody responses to inactivated acute hemorrhagic conjunctivitis (AHC) virus; enterovirus 70 (EV70). Ocul Immunol Inflamm. 2003;11:197–209.
Boger WIII, Peterson R, Robb R. Keratoconus and acute hydrops with congenital rubella syndrome. Am J Ophthalmol. 1981;91:231.
Boniuk V. In: Pavan-Langston D, editor. Rubella and congenital rubella syndrome. in Ocular Viral Disease, International Ophthalmology Clinics, Ed. Boston: Little, Brown; 1975. p. 229–42.
Boniuk V. Rubeola (measles, morbilli). In: Pavan-Langston D, editor. Ocular Viral Disease, International Ophthalmology Clinics Ed. Boston, MA: Little, Brown; 1975. p. 243–56.
Hara J, Fujimoto F, Ishibashi T, et al. Ocular manifestations of the 1976 rubella epidemic in Japan. Am J Ophthalmol. 1979;87:642.
Smolin G. Report of a case of rubella keratitis. Am J Ophthalmol. 1972;74:36.
van Gelderen B, Van der Lelij A, Treffers W, et al. Detection of herpes simplex virus type 1, 2 and varicella zoster virus DNA in recipient corneal buttons. Br J Ophthalmol. 2000;84:1238–43.
De Kesel R, Koppen C, Leven M, et al. Primary graft failure caused by herpes simplex virus type 1. Cornea. 2001;20:187–90.
Thomas M, Robertson W. Dermal transmission of a virus as a cause of shingles. Lancet. 1968;2:1349.
Bowsher D. Trigeminal neuralgia: an anatomically oriented review. Clin Anat. 1997;10:409–15.
Jean WH, Wu CC, Mok MS, et al. Starting dose of gabapentin for patients with post-herpetic neuralgia – a dose-response study. Acta Anaesthesiol Taiwan. 2005;43:73–7.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Kim, Ti., Azar, D.T., Pavan-Langston, D. (2021). Viral Disease of the Cornea and External Eye. In: Albert, D., Miller, J., Azar, D., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-319-90495-5_209-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-90495-5_209-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-90495-5
Online ISBN: 978-3-319-90495-5
eBook Packages: Springer Reference MedicineReference Module Medicine